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ABSTRACT 
 
Von Willebrand disease is the most common inherited bleeding disorder worldwide with 
a prevalence, reaching 1% of general population. vWD is equally distributed between 
genders. However, vWD-affected females experience specific hemostatic challenges 
during menstruation and childbirth. Despite intensive research within the field, there are 
still many unsolved issues, related to the fundamental mechanisms of the increased 
bleeding tendency. This thesis was divided into clinical part (Study I and Study II) and 
fundamental part (Study III and Study IV). The former has explored current management 
options for vWD-patients, suffering from excessive menstrual bleeding and postpartum 
hemorrhage (PPH), respectively. Fundamental part aimed to enhance our understanding 
of the dynamics of hemostasis contributing to excessive menstrual bleeding in women 
with VWD.  
Study I explored the prevalence of heavy menstrual bleeding (HMB) among vWD 
affected females, its impact on everyday life activities and overall health-related quality 
of life. Information was obtained using self-administered forms and medical records. Of 
the 30 women (18-52 years) included in the study, a half (50%) suffered from HMB. This 
occurred despite the fact, that the majority of women received treatment for HMB. 
Almost all women had limitations in their everyday life activities, caused by HMB. The 
overall health-related quality of life was lower with regards to ‘bodily pain’ in women 
with HMB, compared to general Swedish population. Close interaction between 
hematologists and gynecologists is necessary in order to prevent limitations and improve 
quality of life in women with vWD. 
Study II investigated the incidence of PPH in women with vWD, its correlation with i) 
type of vWD ii) levels of vWF and FVIII iii) treatment options. 34 women (59 deliveries) 
occurred in 14 different clinics (years 1995-2012) were included in the study. The 
incidence of primary PPH, severe primary PPH and secondary PPH was 44%, 20% and 
12%, respectively, which is greater than in general population. Women with type 3 vWD 
was at greater risk of experiencing severe primary PPH, compared to other types. Another 
risk factors were instrumental assisted delivery and undiagnosed vWD at the time of 
delivery. FVIII levels during late pregnancy was inversely correlated to blood loss during 
delivery. Therefore, in order to decrease morbidity, we should identify women with yet 
unknown vWD more actively, probably through providing them with the validated self-
administered blood questionnaires in the antenatal settings. Once being diagnosed, vWD 
require comprehended approach, so that PPH could be prevented. 
Study III assessed the changes in hemostatic variables in women with vWD during a 
regular menstrual cycle and compared them with healthy controls. 12 vWD affected 
females (NOT pregnant/breastfeeding/on hormonal treatment) were compared with 102 
healthy controls, matched for age and BMI. In women with vWD, thrombin generation 
profiles were altered, with prolonged lag-time, time to peak and decreased peak thrombin 
concentration, compared to controls. AT was also higher in the study group, which may 
potentially contribute to the excessive bleeding in this cohort. Within the vWD group, 
FVIII and FX were significantly lower during the luteal phase, than in follicular phase. 
The decrease in procoagulant agents prior to menstruation may predispose women with 
vWD to the development of HMB. Therefore, altered thrombin generation dynamics, 
together with increased AT and decline in FVIII and FX prior to menstruation, can 
potentially play role in the excessive blood loss during menstruation in women with 
vWD. 
Study IV explored how do inflammatory and endothelial markers change during the 
menstrual cycle in women with vWD. 12 vWD affected females (NOT 
pregnant/breastfeeding) were compared with 102 healthy controls, matched for age and 
BMI. Within the study group (vWD), endostatin levels were higher during the follicular 
phase, than in luteal phase. Since endostatin inhibits angiogenesis and coagulation, its 
rise during early follicular phase (which corresponds to menstrual phase of the uterine 
cycle) may affect the hemostasis within the uterine cavity and therefore contribute to the 
development of HMB. Women with vWD were different from healthy controls in terms 
of balance between pro- and anti-angiogenic markers, with sICAM-1 and IL-6 being 
higher in women with vWD, compared to controls, while sVCAM-1, cathepsin S and sP-
selectin were lower. The pattern was constant across the menstrual cycle. Hypothetically, 
this imbalance could lead to the formation of angiodysplasia - common complication of 
vWD. The above statement, however, requires verification in larger well-designed 
studies. 
In conclusion; this thesis reports, that the current approaches are still insufficient in terms 
of preventing common vWD complications - HMB and PPH. It emphasizes the 
importance of early diagnosis, providing to the patients the reliable information on drugs, 
proactive management and close collaboration between hematologists and ob&gyn 
specialists. Furthermore, the thesis provides additional knowledge on how do coagulation 
and inflammatory systems change in response to the sex steroids fluctuations during the 
  
menstrual cycle. It reaffirms intimate interactions between coagulation and inflammatory 
systems. Our work suggests, that multiple factors with versatile effects, rather than simple 
decrease in vWF, are responsible for the development of HMB in women with vWD.  
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1 INTRODUCTION 
 
Just then a woman who had been subject to 
bleeding for twelve years came up behind him and 
touched the edge of his cloak. She said to herself, 
“If I only touch his cloak, I will be healed.”  
Jesus turned and saw her. “Take 
heart, daughter,” he said, “your faith has healed 
you.” And the woman was healed at that moment. 
Matthew 9:20-22 
 
 
Throughout the history of mankind, blood has always been considered as an entity, which 
sustains and preserves life. Blood was used in rituals and sacrifices, was a subject of 
controversy, both between medieval doctors and philosophers. Of all body fluids, blood is the 
most sacred one. What Mephistopheles called ‘Blut ist ein ganz besondrer Saft’1. The equating 
of life with blood is natural and inevitable, as life leaves a person when he bleeds to death.  
Despite significant progress in the development of medical science, blood still conceals many 
secrets. And among the most unexplored ones is the enigma of von Willebrand disease.  
It is traditionally stated that the first description of this disease was given by the Finnish doctor 
Erik von Willebrand in the second quarter of the twentieth century (1). Worth mentioning, that 
there are earlier reports, with Minot&Lee (2) were probably the first to describe this disease in 
1920, followed by reports from four independent groups (3, 4). However, today it is impossible 
to say exactly what kind of bleeding disorder was described in every single case, back 100 
years ago. Diagnostic tools were not perfect and many bleeding disorders shared the same 
clinical features. For example, nosebleeds, that are common in patients with von Willebrand 
disease, were previously attributed solely to hereditary telangiectasia (Osler–Weber–Rendu 
disease), to that extent, that ”the possibility of epistaxis being a cardinal symptom of another 
bleeding disease was given little consideration” (5). 
Nevertheless, today this disease deservedly bears the name of Erik Adolf von Willebrand, 
because he was the one who brought the attention to this condition. While reviewing medical 
                                               
1 ‘Blood is a juice of very special kind’ 
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journals, he marked a peculiar fact. There were 19 reported cases of extensive familial 
bleedings. Despite the fact that both women and men were affected, all cases were treated as 
hemophilia. This was in opposite to Nasse’s law formulated in 1820: hemophilia affects only 
boys but is transmitted through females. Was it possible that under the guise of hemophilia 
there was another completely unknown disease? A family from Åland Islands helped him to 
find the answer to this conundrum. 
It all started with 5-years old girl – Hjördis, who was admitted to the hospital with rather severe 
bleeding. Subsequently, she exsanguinated to death during her fourth menstrual cycle at the 
age of 13. Erik von Willebrand discovered that many of her relatives also suffered and even 
died from mysterious bleedings (Figure 1). Surprisingly, bleeding trait was not only more 
common among females (16/35 in women vs. only 7/31 in men), but also manifested in graver 
forms. Year 1925, Federley concluded that in contrast with classical hemophilia, both genders 
are equally affected and the mode of inheritance is dominant. Despite the predominance of 
female bleeders, von Willebrand cautiously described it under the name "hereditary 
pseudohaemophilia" (1). Interestingly, when Rendu for the first time (1896) described 
telangiectasia, a condition that now bears his name, he also called it pseudohaemophilia (6). It 
is understandable, as hemophilia was widely known and thus usually served as the reference 
for other bleeding conditions. 
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Figure 1. Pedigree of the family described by Erik von Willebrand (so called Family S). The index case (Hjördis) 
is in the second row, #16. Reproduced with permission from Thieme Group from D. Nyman et al. Recent 
Investigations of the First Bleeder Family in Åland (Finland) Described by von Willebrand. Thromb Haemost 
1981; 45(01): 073-076.  
 
Rigorous analysis of the clinical features and blood tests helped Erik von Willebrand to 
distinguish the new disease from thrombocytopenic and anaphylactoid purpurae and also from 
thrombasthenia, described by Glanzmann (7). 
During next decades, there were several scientific trips to Åland, usually when a new laboratory 
method became available. Unfortunately, most of these investigations did not result in any 
clarification. New theories emerged, so did the names of the disease: pseudo-haemophilia (8-
10), vascular haemophilia (11-14), angiohaemophilia (15-18). Willebrand-Jurgens syndrome 
(19, 20), Minot-von Willebrand syndrome (5). 
In the 1950s new methods contributed to determination of the antihemophilic factor (AHF), its 
low level was subsequently associated with prolonged bleeding time (8, 10, 13, 17, 21, 22). At 
the same time, half of the vWD patients also had positive tourniquet test and/or morphological 
abnormalities in capillaries, suggesting a defect in the vessel wall (13, 23). 
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The next step was taken by Blombäck&Blombäck, scientist couple from Sweden, who 
succeeded in purifying and concentrating AHF in so called plasma fraction I-0 (24). Together 
with Nilsson they went to Åland and discovered that out of sixteen patients with von 
Willebrand disease all but one had decreased levels of AHF - a defect, which, however, could 
be corrected by I-0 fraction (25). Surprisingly, they also found that even if I-0 fraction was 
prepared from hemophiliac’s blood (and therefore contained almost no AHF), it could still 
correct bleeding time in patients with von Willebrand disease. It became obvious, that there 
was a specific plasma factor, different from AHF, that is lacking in patients with von 
Willebrand disease. It took another 30 years to purify and establish the ultimate sequence of 
the lacking plasma protein (26-29). In memory of the great scientist, the protein was called – 
von Willebrand factor. 
1.1 VON WILLEBRAND FACTOR 
von Willebrand factor (vWF) is a large multimeric blood glycoprotein with versatile functions 
both within and beyond the hemostasis. 
vWF gene is located on the short arm of chromosome 12 and composed of 178 kilobases (52 
exons) (26, 27, 30). Megakaryocytes and endothelial cells are the primary sites of the vWF 
production. 
vWF is initially produced as a large precursor protein, containing 2813 amino acids, which 
subsequently goes through extensive posttranslational modification. The signal sequence (aa 
1-22) and the propeptide (aa 23-763) detach sequentially from the molecule. Remaining subunit 
(aa 764-2813) corresponds to mature vWF monomer. These monomers then merge into pairs 
within the endoplasmic reticulum, through binding the C-terminals with disulfide bonds (31). 
Further modifications take place in Golgi and post-Golgi compartments and include fusion of 
the dimers into multimers of different sizes. The latter may range from 500 000 to more than 
20 000 000 daltons. Observations testify, that the larger multimer is, the more binding sites for 
collagen and platelets it provides, i.e. the more active it is. Multimers of smaller size are 
constitutively secreted into the plasma, while the bigger ones are stored in platelets and 
endothelial cells, waiting to be released in response to external stimulation (epinephrine, 
histamine, thrombin, estrogen or vasopressin analogue D-amino D-arginine vasopressin - 
DDAVP) (32-34).  
vWF is not only stored within α-granules in platelets and so called Weibel-Palade bodies in 
endothelial cells, but rather actively interplays with them. It was shown that proper compaction 
of otherwise massive vWF multimers not only sustains typical rod-shape of Weibel-Palade 
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bodies, but also plays an important role in fast exocytosis. Long filaments of vWF are stored 
densely packed into tubules, which prevents them from tangling and also promotes rapid 
unfolding at the time of exocytosis (35). The actin filaments that make up the cytoskeleton, in 
turn, take an active part both in preventing and augmenting vWF exocytosis (36). Single 
Weibel-Palade bodies can exocytose individually or several organelles can fuse within the cell 
in order to produce large secretory pods prior to release of vWF (37). 
Role distribution between the vWF derived from platelets and endothelial cells is currently 
debatable (38, 39). 
vWF structurally consists of several domains (Figure 2), each of them has a specific function: 
• D’D3 assembly provides the binding site for FVIII (coagulation factor VIII) (40); 
• A1 - binding sites for platelet GPIb, collagen, heparin, and ristocetin (41-43); 
• A2 – binding site for cleaving protease ADAMTS13 (a disintegrin and 
metalloproteinase with a thrombospondin type 1 motif, member 13) (43, 44); 
• A3 – primary binding site for collagen (43); 
• C4 – binding site for platelet receptor GpIIb/IIIa (45); 
• CK – dimerization interface (45). 
 
 
Figure 2. Schematic illustration of vWD domains  
 
Such a complicated structure plays though an important physiological role, as conformational 
changes in vWF domains can modulate the ultimate blood clotting functions (46). 
In addition to participating in primary hemostasis, through binding to the exposed 
subendothelial matrix, vWF is a major player within the secondary hemostasis. This activity is 
due to vWF ability to bind FVIII. It is important to note, that this binding is size-independent, 
i.e. vWF multimers of different size may participate (47). FVIII is highly dependent on vWF, 
since the latter serves as the carrier. In the absence of vWF, FVIII undergoes proteolytic 
cleavage five times faster (48, 49). 
Obviously, vWF also plays a significant role in pathogenesis of the thrombotic diseases, such 
as thrombotic thrombocytopenic purpura, ischemic stroke and coronary heart disease (50-53). 
  6 
New therapies based on inhibiting vWF activity are currently under development (54). Overall, 
being an acute phase reactant, vWF may fluctuate due to many pathological and physiological 
conditions. These determinants include, but is not limited to gender, nation and race, phase of 
menstrual cycle, stress and exercise. 
vWF spatial conformation, and hence its functional activity, depends on rheological 
characteristics of blood, and primarily, the shear force. Interestingly, vWF is the only plasma 
protein able to operate in high shear stress environment (more than 50,000s-1) (55). While under 
low shear stress conditions vWF remains in globular form, with its active binding sites 
concealed. When the shear force increases, vWF elongates, revealing its receptors for platelets 
and fibrinogen. Moreover, binding site for the cleaving protease - ADAMTS13 becomes 
accessible, which is essential in vWF down-regulation (56). ADAMTS13 cleaves large vWF 
multimers (cleavage site - A2 domain) into smaller, less active ones (57, 58). Wu et al. had 
cleaved vWF into smaller peptides and identified 24 amino acid sequence (pro1645 – lys1668) 
as the shortest peptide that can competitively bind to ADAMTS13 (57). This suggests existence 
of complementary sequence at ADAMTS13. Average half-life of normal vWF in plasma is 8-
12 hours. However, it is usually shortened in people with blood group 0 (see Epidemiology 
section for possible explanation). 
Animal studies indicate, that vWF inactivation occurs in the macrophages of the spleen and 
liver (59). However, spleen contribution to the process is limited, as evidenced by monitoring 
patients after splenectomy. In asplenic patients DDAVP administration results in vWF rise and 
subsequent decline, comparable to that of healthy individuals’ (60).  
The complex structure and versatile functions of the vWF not only ensure its participation in 
many physiological processes, but, unfortunately, also contributes to the development of the 
versatile diseases and first of all - von Willebrand disease. 
1.2 CLASSIFICATION OF VON WILLEBRAND DISEASE 
Impairment in vWF function arises either from quantitative deficiency or qualitative 
alterations. Based on that all cases of vWD are classified into one of three types. 
1.2.1 Type 1 
Type 1 is the most common form of vWD, accounting for 75-80% of all cases. It arises from 
partial quantitative deficiency of vWF, which may result in bleeding tendency of various 
degree, from mild to severe. 
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vWF level strongly correlates with bleeding risk. vWF levels <30 IU/dL are associated with 
clinical severity and presence of mutations in vWF gene (61, 62).  
Cases clinically consistent with type 1 vWF are heterogeneous in relation with causative 
mutations. For instance, R760H mutation results in concordant decrease in vWF:Ag, vWF:RCo 
and vWF:CB, with preserved multimer pattern (63). Several mutations (C1149R, Y1584C) 
result in intracellular retention of vWF and its consequent decreased plasma levels (64, 65). 
Y1584C also makes vWF susceptible to proteolysis (66). 
A very specific subtype, Vicenza, arises from the replacement of Arg-1205 by His and is 
characterized by increased vWF clearance and presence of ultra-large multimer, similar to 
those occurring after DDAVP infusion (67, 68). This was confirmed in animal studies, where 
recombinant R1205H vWF was infused in vWF-deficient mice and had shortened survival 
compared with wild-type vWF (0.3h vs. 2.8h respectively) (69). 
Mutations may have different penetrance and in some cases are exacerbated by O-blood group 
(70). At the same time, specialists currently agree that there is no need to conduct routine 
mutation analysis among patients with clinical symptoms corresponding to type 1. However, 
this approach could be helpful in establishing accurate diagnosis in unclear cases. 
1.2.2 Type 2 
Type 2 vWD embraces four subtypes that are all characterized by qualitative changes in the 
structure of the vWF. 
In contrast to type 1, in which vWF levels confidently predict bleeding, other variables such as 
platelet count, absence of large multimers or exact mutation determine bleeding tendency in 
type 2 vWD. Clinical and familial history is also of a great value (71).  
1.2.2.1 Type 2A 
Type 2A is primarily characterized by loss of the most active large and ultra-large multimers. 
Experiments on cell cultures transfected with mutant vWF allowed to detect two possible 
mechanisms of “large multimers loss”. Several mutations cause defect in intracellular transport 
of vWF, which becomes retained within the cell, even upon secretagogue stimulation (72). It 
is assumed, that larger multimers, containing more defective monomers are more likely to 
linger within the cell. It results in relatively more efficient secretion of smaller multimers – 
typical laboratory pattern of the subtype 2A. An alternative mechanism may be due to the 
increased cleavage of predominantly large multimers. In latter case synthesis and secretion of 
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larger multimers remain unaffected, but they undergo rapid proteolysis moderated by specific 
plasma protease, possibly a calpain (73-75). These assumptions are confirmed by preservation 
of multimer structure in platelet vWF (stored in α-granules) and secretion of intact multimers 
in transfection cell studies (72). 
It is not unusual that vWF-platelet interaction is also disrupted. With several exceptions, 
desmopressin administration is usually ineffective in patients with type 2A, as it results in 
secretion of hemostatically dysfunctional units of vWF (76, 77). 
1.2.2.2 Type 2B 
Type 2B accounts for 5-8% of all vWD cases. It is characterized by gain-of-function in A1 
domain, viz. increased affinity of vWF to platelet receptor complex GpIb/IX/V (78, 79). It 
results in spontaneous vWF/platelet binding and subsequent clearance from circulation, at that 
larger multimers, being more active, bind vigorously to the platelets. Ultimately, it leads to a 
very specific laboratory pattern and clinical manifestations. For instance, desmopressin 
administration in patients with type 2B may result in increased bleeding tendency due to 
accrescent thrombocytopenia and thus DDAVP is contraindicated in this cohort (80). 
Thrombocytopenia is also usually aggravated during conditions associated with short or long-
term rise in vWF, such as pregnancy, surgeries or infections (81-83). Worth mentioning that 
thrombocytopenia represents an independent bleeding risk in type 2B patients (84). 
The identification of vWF gene mutations in suspected type 2B cases allows its distinction 
from so-called platelet-type vWD, characterized by a similar phenotype but with mutations 
located in the platelet GpIb receptor (85). 
1.2.2.3 Type 2M 
In type 2M alterations in vWF structure are similar to those in type 2B in the sense of affected 
domain – A1. However, phenotype is completely the opposite, manifesting with loss-of-
function abnormalities. vWF exhibits decreased ability to bind with platelets, whereas its 
multimer distribution usually remains unaffected. 
DDAVP administration is usually of no effect, albeit test dose may be prescribed to evaluate 
individual response. 
1.2.2.4 Type 2N 
Unlike other subtypes, type 2N is inherited as autosomal recessive trait. 
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Type 2N represents qualitative defect in vWF causing altered binding to FVIII. The latter 
becomes vulnerable to rapid proteolysis. 
The identification of type 2N mutations, which is suspected in the presence of a marked 
reduction in FVIII:C in comparison to vWF and is confirmed by the FVIII-vWF binding test 
(vWF:FVIIIB), is important for genetic counseling to exclude the presence of the state of 
carrier for hemophilia A. It is not unusual that clinical picture in type 2N vWD patients 
resemble to hemophilia, primarily due to significantly decreased levels of FVIII and, as a result, 
soft-tissue bleeding. However, in opposite to X-linked hemophilia, type 2N vWD show 
autosomal recessive inheritance. 
Some patients with type 2N may benefit from DDAVP administration, though altered binding 
to FVIII may sometimes counteract rise in plasma vWF levels (86). In other cases vWF-
containing concentrates are preferable. 
1.2.3 Type 3 
Type 3 is the most rare type of vWD, with only 0.1-5.3 cases per million population, varying 
significantly between countries (87-89).  
At the same time, it is the most severe type manifesting with life-threating bleeding. It is 
characterized by dramatical decrease in vWF levels (almost ultimate absence in some cases). 
Thus, patients with type 3 vWD usually become symptomatic early during infancy or when 
they become mobile. Consanguinity is a frequent finding among patients with type 3 vWD (90, 
91). 
In conditions of severe vWF paucity FVIII, left unprotected, undergoes rapid cleavage. Thus, 
clinical picture in type 3 vWD patients may mimic hemophilia (92). However, vWD usually 
manifests with mucocutaneous bleedings in contrast to hemophilia, in which soft-tissue 
bleedings are more common. Lak et al.(91) performed large comparative study between 385 
patients with type 3 vWD and 100 age-matched hemophiliacs and reported certain differences. 
Menorrhagia and epistaxis were more common, as expected, among vWD patients than in 
patients with hemophilia (p<0.0001), while hemarthrosis and muscular hematomas were more 
frequent among patients with hemophilia (p<0.0001).  
DDAVP is ineffective in the vast majority of cases, due to critical lack of vWF reserve in depot. 
Plasma derived factor concentrates or recombinant coagulation factors normally become a 
method of choice. Nevertheless, this approach occasionally leads to the unwanted sequalae to 
be described in the “Treatment” section. 
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1.2.4 Acquired vWS 
Year 1968, Simone et al. (93) reported an intriguing clinical case. A young boy was admitted 
to the hospital with complaints and clinical picture consistent with von Willebrand disease. 
However, his increased bleeding tendency was recent in onset and none of his relatives 
experienced prolonged bleeding episodes. Coagulation tests were also normal in his relatives. 
Later he was diagnosed with systemic lupus erythematosus, which required administration of 
corticosteroids. Bleeding symptoms disappeared shortly after initiation of therapy and did not 
return even after cessation. It all led to belief that bleeding syndrome was acquired rather than 
inherited and it was named “acquired von Willebrand syndrome (avWS)”. 
avWS is an uncommon condition with slightly more than 700 cases reported (94). However, 
real numbers can hardly be established, due to the fact that not all patients are diagnosed and 
not all cases are reported. avWS occurs in any age, though is more common in elder, with 
median age of onset being 62 years (95). 
AvWS is always secondary to the main disease. Federici et al. (95) analyzed data from an 
international register (186 cases) and discovered that avWS was related to: 
• lymphoproliferative/myeloproliferative disorders in 63%,  
• cardiovascular disorders – 21%,  
• solid neoplasms - 5%,  
• autoimmune diseases – 2%,  
• miscellaneous disorders – 9%. 
Another common primary condition giving rise to avWS is hypothyroidism. Bleeding tendency 
and related laboratory abnormalities normalize with rare exceptions (96) after substitution 
therapy with levothyroxine (96-98). Several drugs, such as ciprofloxacin (99), valproic acid 
(100) and griseofulvin (101) were also reported being the possible provoking agents. 
Several possible mechanisms of pathogenesis were proposed: 
• High shear-stress induced disintegration. vWF is extremely dependent on 
hemodynamical conditions in blood flow. In high shear stress milieu vWF unfolds and 
elongates, making its otherwise cryptic cleavage sites susceptible for ADAMTS13. It 
usually occurs in the settings of pronounced vessel obstruction, due to atherosclerosis, 
malformations or valvular heart disease (102, 103). Several iatrogenic conditions are 
also responsible for avWS – placement of left ventricular assist devices or artifical 
valves, as they also may cause high shear forces (104, 105). 
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• Formation of antibodies against vWF or vWF/FVIII complex. This is potentially 
applicable to the autoimmune diseases, monoclonal gammopathies and 
lymphoproliferative disorders (106-108). Certain antibodies may be more directed 
towards larger multimers, explaining typical “large multimer loss” pattern. 
Interestingly, it seems like antibodies may cross the placenta, causing transient avWS 
in baby (109). 
• Adsorption onto cells. Certain type of cells are able to precipitate vWF on their surfaces 
and in this way take it out of circulation. Possible candidates are malignant cells or 
abnormal lymphocytic clones in multiple myeloma, Wilms tumor or non-Hodgkin 
lymphoma (110). 
• Othere causes are relatively rare and may include reduced synthesis, e.g. in 
hypothyroidism (97, 111), or proteolytic cleavage of vWF by proteases other than 
ADAMTS13 (112).  
• Multicausality is also possible.  
1.3 EPIDEMIOLOGY 
Von Willebrand disease is considered to be the most common inherited bleeding disorder with 
1% of general population having decreased levels of vWF upon laboratory investigation. 
However, numbers vary significantly depending on calculation method. Clinically evident 
vWD occurs 100 times less often with prevalence of 3-10 cases per 100000. In Nordic countries 
prevalence is 8 per 100000 inhabitants (113). However, even in this proportion, vWD cause 
significant effects, both at individual and socio-economic levels. Recent Swedish study 
reported that patients with vWD are twice more frequently hospitalized (inpatient and 
outpatient) than controls (114). 
In severe cases equal male:female ratio is obvious, in contrast to milder forms, which are 
more often diagnosed in women, probably due to hemostatic challenges during menstruation 
and childbirth (115). 
vWD is present everywhere across the globe. However, it may be of a clinical importance to 
keep in mind, that Caucasians generally have lower vWF levels compared to African 
Americans (116, 117). 
Interestingly, people with blood-group O have lower levels of vWF in plasma (up to 35% less). 
The reason for that probably lies in the structural features of vWF. ABO determinants link to 
vWF during glycosylation process. It is believed that these carbohydrates play an important 
role in vWF polymerization and also determine clearance of vWF. ABO significantly 
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accelerates vWF clearance from plasma, but does not influence its production or secretion. It 
is confirmed by increased ppvWF/vWF ratio and rapid decrease in vWF levels after DDAVP 
administration (118). High heterogeneity of vWF levels in different blood groups makes ABO-
specific reference ranges a reasonable approach (119, 120). When comparing with standard 
donor plasma, vWF levels may fluctuate from 75% for blood group O to 123% - for AB (119). 
Overall, type 1 vWD is the most common type, accounting for up to 70% of all vWD cases. 
Type 2 is responsible for 25% of cases, while subtypes prevalence distributes in following order 
– 2A>2N>2M>2B (121). Type 3 is the most rare one with less than 5% affected. 
 
1.3.1 Animals 
vWD-like conditions is encountered not only in humans, but also in many animal species. 
While mice are used as vWD models, other animals, such as dogs, cats, horses and pigs develop 
vWD naturally (122-128). vWD was described in dozens of dog breeds, with extreme high 
prevalence in certain ones – 43% of Corgi and up to 73% of Doberman Pinschers are affected 
(Figure 3) (127, 129). 
Interestingly, animal studies suggested that vWD might provide some resistance against 
atherosclerosis and bacterial endocarditis (130, 131). Unfortunately, it has never been 
demonstrated in humans.  
Figure 3. Corgi and Doberman Pinschers are often affected with vWD 
Picture of Welsh Corgi by Bensbro at Wikimedia Commons, licensed CC BY-SA 4.0 
https://commons.wikimedia.org/wiki/File:WelshCorgi.jpeg 
Picture of European Dobermann by Ilicivan at English Wikipedia, public domain 
https://commons.wikimedia.org/wiki/File:European_Dobermann.jpg 
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1.4 CLINICAL PRESENTATION  
Von Willebrand disease usually manifests with mucocutaneous bleedings. Soft tissue 
hemorrhages similar to those in hemophilia are rare and occur in case of significant decrease 
in vWF and, as a consequence, FVIII. However, clinical symptoms may vary considerably due 
to the heterogenous nature of vWD. The most frequent symptoms with corresponding 
prevalence among patients with vWD are shown at Figure 4 (132). 
 
Figure 4. A. Most frequent clinical symptoms of vWD in both genders. B. Prevalence of heavy menstrual bleeding 
and postpartum hemorrhage in female vWD patients. Colored segments illustrate the percentage of vWD-affected 
patients experiencing the exact symptom.  
However, clinical symptoms may be rather extraordinary. Argyris et al. (133) and Ozhan et al. 
(134) reported two cases of maxillary pseudotumors as a manifest of vWD (type 2N and type 
3, respectively). According to the histological examination, lesions were characterized by 
cystic spaces filled with organizing hematoma. Previously, maxillary pseudotumor was 
considered a rare complication of hemophilia A or B, with less than 30 cases reported. 
It was established that vWF levels are inversely correlated with angiogenic cytokines and 
circulating endothelial cells, which results in increased angiogenesis in vWD patients (135, 
136). Microscopical evaluation of the capillaries in vWD patients testifies the presence of 
  14 
structural alterations – capillaries are tangled, with irregular contour and fail to constrict 
properly (23, 137). 
Decreased clotting potential together with alterations in angiogenesis may act jointly, 
predisposing individual to vascular abnormalities, such as Dieulafoy’s lesions or 
pseudoaneurysms (138). Pseudoaneurysms of different localizations (aa. supraorbitalis, glutea 
superior, hepatica, temporalis superficialis, uterina) were previously reported in patients with 
vWD (139-143). Another possible complication is the formation of arteriovenous 
malformations in vWD patients. However, no comparative studies between vWD and non-
vWD patients in regards to prevalence of arteriovenous malformations were performed to date. 
Nevertheless, reported cases emphasize the necessity to suspect structural lesions in vWD 
patients with intracranial hemorrhage and resist the temptation to attribute it only to the 
bleeding tendency and previous trauma, as it may significantly affect management and 
prognosis (144).  
Angiodysplasias are also a common findings in patients with vWD, especially when 
gastrointestinal bleeding is present. It was reported that angiodysplastic lesions occur in up to 
10% of vWD affected patients (145). Angiodysplasia may affect any part of the gastrointestinal 
tract, from tongue to colon (146, 147). One of the hypothesis links frequent occurrence of 
angiodysplasia in vWD patients to angiogenesis enhancement (148). Interestingly, it was 
shown that FVIII expression is reduced in endothelial cells within the affected areas, while 
remaining normal in non-ectatic regions (149). This hypothetically implies a close relationship 
between alterations in angiogenesis and coagulation. However, it is still debatable whether 
vWF deficiency predisposes to angiodysplasia formation or barely instigates bleeding onset 
from preexisting vascular anomalies. Dysplastic vessel regions are vulnerable and may cause 
recurrent gastrointestinal bleedings. Current treatment options are thalidomide and its 
derivative lenalidomide, although administered off-label (150). 
In addition, there were reports of a greater spread of mitral valve prolapse among patients with 
vWD disease than in age, sex-matched controls (60% vs. 13.3%, p<0.01) (151). Overall, co-
existence of vWF deficiency and disorders, accompanied with mesenchymal dysplasia 
(skeletal abnormalities, dysplastic vessels, Ehlers-Danlos syndrome) suggests, that vWF may 
play a major role in the development and functioning of mesenchyme (152). 
1.4.1 Heavy menstrual bleeding 
The very first patient described by Erik von Willebrand was a young girl – Hjördis, who 
unfortunately bled to death during her fourth menstruation. Excessive cyclic bleedings still 
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remain a significant problem in vWD-affected females. The situation is complicated by the fact 
that in the modern world, reproductive behavior has dramatically changed. Today, women 
experience 10 times more menstrual periods than their ancestors (153). 
There are obvious difficulties with the precise assessment of menstrual blood loss. 
Furthermore, classification approaches may differ and therefore it is not unusual that the term 
heavy menstrual bleeding (HMB) is defined differently. However, an accepted boundary is the 
blood loss exceeding 80 ml per menstrual cycle (154).  
HMB is usually reported as a major complication of vWD. According to the systematic review 
performed by Shankar et al. (155) up to 13% of HMB cases have vWD as the underlying cause. 
Conversely, 73% of vWD-affected women were found to have objectively confirmed HMB 
(156). Depending on the method of calculation, this figure can reach horrendous 93%, which 
significantly exceeds the prevalence of HMB in the general population (10% in Sweden) (157-
159). It is still not uncommon in modern Sweden, where heavy menstrual bleeding is in top 
three most frequent causes of hospitalization among vWD patients (together with 
gastrointestinal bleedings and epistaxis) (114). 
Heavy menstrual bleeding may significantly affect woman’s life. In Sweden, more than half of 
patients with HMB reported avoiding social activities during their periods (160). Sometimes, 
menstrual blood loss is so devastating that the only way towards the ultimate cure is 
hysterectomy. In 1968 Taylor stated: “When menorrhagia is so severe as to require repeated 
transfusions consideration might be given to the induction of an artificial menopause, but in 
most cases hysterectomy would appear to be the treatment of choice” (161). Unfortunately, 50 
years later we still cannot avoid removing the uterus in some cases. Today, half of women 
undergoing hysterectomy for HMB have no organic pathology and some of them may have 
unrecognized vWD (90). 
In a recent survey, which involved ob&gyn specialists, it was found that bleeding disorders, 
inter alia von Willebrand disease, were included in the differential diagnosis of heavy 
menstrual bleedings in 77% of adolescents and only in 39% of women of reproductive age 
(162). Ten years earlier, a similar survey reported even lower figures – 16% and 4%, 
respectively (163). Alertness regarding bleeding disorders has obviously grown among medical 
doctors, but is it sufficient? According to the recent study by Jacobson et al. it is not, because 
most of the adolescents, experiencing HMB do not undergo screening for vWD (164). 
The situation is so emerging that it has been proposed to test for underlying vWD in any case 
of menorrhagia and no obvious pelvic pathology (132). 
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It was stated that HMB has a larger impact on women with bleeding disorders than on women 
with unaffected hemostasis (165). Excessive bleeding during menstruation is a well-known risk 
factor for developing iron-deficiency anemia and there are implications for women’s social 
activities. Barr et al. (166) reported that women with vWD were less inclined to engage in post-
secondary education, probably due to the anemic state. 
Today, several management options (described in detail in “Treatment” section) are available 
to help women with vWD to normalize their menstrual blood loss, and, as a consequence, 
prevent unwanted complications. However, it is not yet well established whether provided 
treatment options are good enough to improve overall quality of life. 
1.4.2 Postpartum hemorrhage 
Another significant problem, which women with vWD face, is the bleedings that occur during 
or soon after childbirth. In late pregnancy, 15% of cardiac output falls on the uterine circulation 
with minute blood flow of 500-700mL. If coagulation system fails to establish effective 
hemostasis shortly after delivery, severe bleeding occurs.  
Postpartum hemorrhage (PPH) is the obstetrical emergency affecting 14 millions women 
worldwide every year (167). It is responsible for more than 100,000 maternal deaths per year, 
or 1 death in 4 minutes. Prevalence of PPH varies significantly across the world, ranging 2-
11% (168). Worldwide, rate of PPH increased from 1.5% in 1999 to 4.1% in 2009 (169). 
Overall, PPH is the leading cause of maternal death worldwide and the problem becomes even 
more pronounced in women with bleeding tendency.  
PPH is traditionally classified as primary and secondary. Primary PPH corresponds to blood 
loss of 500ml or more, while severe primary PPH - 1000ml or more within first 24 hours from 
delivery. Secondary PPH relates to any excessive bleeding, occurring up to six weeks 
postpartum, regardless of volume (170, 171). 
Pregnancy is considered to be the prothrombotic state with range of coagulation factors 
(including FVIII and vWF) rising during gestation (172, 173). However, in patients with 
bleeding disorders this increase is less pronounced (174, 175). After delivery, levels of 
coagulation factors decrease rapidly, predisposing women, and especially those with bleeding 
disorders, to PPH. 
1.5 DIAGNOSTICS 
A recent report from USA (>32,000 patients) announced frequent misrecognition of vWD, with 
quarter of patients visiting the same doctor at least twice with complaints about bleeding 
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episodes. Within a year from the first visit to the specialist, 37% of vWD patients had no 
diagnostic test (176). 
The classical diagnostic triad necessary for the diagnosis of vWD includes bleeding episodes 
previously in life, positive family history and low levels of plasma vWF. Nevertheless, there 
are justifiable doubts that these criteria are exhaustive. Having studied clinical data from 139 
vWD patients, Alamin and Satti (177) concluded that only 65.5% of patients meet minimum 
criteria. 
Of these three components, bleeding history is probably the most important both for diagnostics 
and prognosis. Tosetto et al. (61) compared the efficacy of integral bleeding score (calculated 
by summing up spontaneous bleedings) with laboratory measurement of FVIII and vWF levels. 
Bleeding score was equally effective for the prediction of bleeding after tooth extraction, while 
it turned out to be superior to coagulation tests in predicting bleeding after surgery. Today, a 
number of validated bleeding questionnaires are available, including self-administered and 
pediatric versions (178). Unfortunately, despite undeniable utility of the bleeding scores they 
still have certain limitations (179).  
A the same time, no bedside test specific for vWD is currently available. Bleeding time (BT) 
is considered an imperfect diagnostic tool, since many patients remain within the refence 
ranges. For instance, Fressinaud et al. (180) reported that almost half of patients with type 1 
and one fifth of those with type 2A vWD had normal BT. Global hemostatic testing, such as 
thrombin generation assay, is considered to be superior to classic tests, as the former could 
provide comprehensive knowledge on the entire coagulation system. 
Laboratory testing for bleeding disorders is often challenging due to the fact, that both 
preanalytical and analytical conditions may substantially affect the ultimate results. For 
instance, Favaloro et al. emphasized the importance of proper mixing of thawed plasma 
samples. Non-mixing resulted in 25% decrease in coagulation factors, which may lead to false 
positive diagnosis of vWD (181). Another example is the potential loss of FVIII and vWF 
(predominantly high-molecular weight multimers) if using serum instead of citrated plasma. 
Even minor errors, such as under-filling the tubes, may lead to excess in citrate concentration 
and subsequent false results. Taking together, it all makes an accurate diagnosis of vWD 
extremely challenging, especially in the resource-limited conditions. 
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1.6 MANAGEMENT 
1.6.1 Antifibrinolytic drugs 
Antifibrinolytics, such as ε-aminocaproic and tranexamic acid (TA) are often used in vWD 
patients to control bleedings. The basis for their use is the rich fibrinolytic activity of mucosal 
tracts – the source of most bleedings in vWD. Antifibrinolytics alone may be sufficient to 
control less severe forms of bleedings or can be used as adjuncts to desmopressin or factor 
concentrates. 
Both women suffering from HMB or PPH may benefit from using antifibrinolytic drugs. A 
recent report from an international, randomized, double blind, placebo-controlled trial named 
WOMAN assessed the efficacy of TA in reducing postpartum morbidity, mortality and 
hysterectomy rates (182). The trial lasted 6 years (2010-2016) and included more than twenty 
thousand women. Authors concluded that TA significantly reduces bleeding. They also 
stressed the importance of giving TA as soon as possible after bleeding onset. 
1.6.2 Desmopressin 
Desmopressin (trade name DDAVP®) is a type 2-vasopressin receptor agonist and it causes 
release of vWF from depot. Desmopressin has no uterotonic effect and can be safely used in 
pregnant women before invasive procedures (amniocentesis or villus sampling) with no 
bleeding complications (183). Recent systematic review also confirmed its safety and efficacy 
in PPH prophylaxis among women with bleeding disorders (184). Desmopressin may cause 
hyponatremia if combined with abundant fluid intake, and thus electrolytes should be 
monitored carefully, especially in infants and elderly people. 
Patients are more likely to respond adequately to desmopressin stimulation, if they have normal 
vWF structure, e.g. if they belong to type 1 (76, 77). Moreover, one may expect satisfactory 
response if preinfusion levels of FVIII and vWF are at least 10-20% of normal (185). Therefore, 
desmopressin is contraindicated in patients with type 2B, as it results in secretion of 
dysfunctional vWF, which rapidly binds to platelets causing thrombocytopenia (80). In 
addition, the drug should be used with caution in patients with severe atherosclerosis. Upon 
desmopressin stimulation larger vWF multimers release and they may become highly 
thrombogenic under high shear stress conditions (atherosclerotic plaques) (186-188). 
Individual response to desmopressin is usually constant over time and therefore giving a test 
dose is probably a suitable approach to estimate how does exact patient respond (189). Rise in 
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vWF levels lasts for 8-10 house, which determines the mode of administration – every 12-24 
hours (190). 
1.6.3 Plasma-derived vWF/FVIII factor concentrates 
Initially, plasma-derived vWF/FVIII factor concentrates were developed for the treatment of 
hemophilia. Today, they prove to be the treatment of choice in vWD patients, unresponsive to 
desmopressin (185). However, there are several concerns related to plasma-derived vWF/FVIII 
factor concentrates. Despite many of the measures taken, such as viral screening and 
attenuation, there is still a risk of the pathogen persistence in these products (191, 192). In 
addition, due to their plasma origin, factor concentrates contain extraneous proteins that may 
provoke severe allergic reactions (193). Secondly, different products vary significantly in 
regards to precise coagulation factor levels, vWF/FVIII ratio and presence of the most active 
large vWF multimers (194-197). All the above mentioned parameters certainly affect the 
efficacy and safety of the exact product. For instance, an unbalanced vWF/FVIII ratio can lead 
to a significant increase in plasma FVIII levels, which multiplies the risk of thromboembolic 
complications (198). Therefore, it is recommended to maintain FVIII levels at a maximum of 
250-300 IU/dl during replacement therapy (199). 
One should take into account, that vWF/FVIII concentrates predominantly sustain the plasma 
pool of vWF, without being able to replenish its depot within the endothelial cells and platelets. 
This is a probable reason for lower efficacy of the concentrates in vWD patients, suffering from 
gastrointestinal bleedings due to angiodysplasia, compared with bleeds at other sites (200).  
Another drawback is related to the antibody formation. Up to 15% of patients who have 
received multiple transfusions develop antibodies against vWF. vWF containing products are 
contraindicated after this complication has occurred, since it may lead to the life-threatening 
anaphylactic reactions (201, 202). Important to notice, that being the polyclonal IgG they may 
cross the placenta and cause transient vWD in fetus. In patients with anti-vWF antibodies 
FVIII-only products should be used. 
1.6.4 Recombinant vWF 
Baxalta Inc. has recently introduced recombinant vWF (rvWF) under the name Vonvendi®. In 
contrast to plasma derived vWF/FVIII concentrates, rvWF does not contain FVIII, which 
allows obviating FVIII related risk of thrombosis (203). Another advantage of rvWF is the 
presence of large and ultra large multimers – the most beneficial ones for substitution in patients 
with type 2A, 2B and 3. At the same time, rvWF remains available for ADAMTS13 cleavage, 
ensuring its proper lifecycle (204). 
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Recombinant FVIII contains no vWF and thus is unsuitable in case of severe vWF deficiency. 
In the absence of its carrier FVIII undergoes rapid cleavage in the bloodstream. However, 
recombinant FVIII remains an option for those patients who have developed anti-vWF 
antibodies. 
1.6.5 Treatment for gynecological complications 
In treating gynecological bleedings several treatment options are available in addition to 
conventional management. This includes predominantly hormonal treatment, although surgical 
approaches are also present.  
Combined oral contraceptives (COCs) are both estrogen and progesterone containing 
medications. COCs is currently accepted as the initial treatment for menorrhagia in the general 
population. The positive effect in the treatment of vWD-related excessive menstrual bleedings 
predominantly builds up from two mechanisms. Firstly, it is a reduction in the amount of blood 
loss typical for many modern COCs, as well as the possibility to control the timing of 
menstruation by changing the regimen. Secondly, estrogen is known to increase blood vWF 
levels, which leads to amelioration of the bleeding symptoms (205). However, the individual 
satisfaction rate for COCs, varies significantly depending on the vWD type and COCs’ 
compound (206, 207).  
Levonorgestrel-releasing intrauterine system (LNG-IUS) is a tiny hormone-containing device, 
placed inside the uterus, which provides contraceptive effects and reduces significantly 
monthly blood loss. This effect is also present in vWD cohort with the majority of women 
reporting decrease in the amount of bleeding and more than half become amenorrhoeic (208).  
Surgical options are chosen when conservative treatment fails to provide effective hemostasis 
or in order to stop an acute severe bleeding. Endometrial ablation, which implies destroy of 
endometrial lining through cryo/thermal ablation or endomyometrial resection, is currently 
employed as an alternative to hysterectomy (209). However, the overall efficacy of ablation 
does not reach 100%, which necessitates repeat procedure or ultimate removal of the uterus. 
Hysterectomy rates remain high among vWD patients, somewhat varying between the vWD 
types: 8-18% in type 1 patients and 23% in type 2 and 3 vWD patients (156, 206, 207).
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2 AIMS OF THE THESIS 
During the project we aimed to evaluate the impact of von Willebrand disease on women’s 
everyday life, with special attention to the most common bleeding complications: heavy 
menstrual bleeding and postpartum hemorrhage. We intended to assess current management in 
terms of its rationality and sufficiency for prevention of bleeding episodes. An important goal 
was to scrutinize the possible reasons for developing bleeding complications, which would help 
to ameliorate clinical management of the patients and ultimately improve their quality of life. 
Furthermore, we took aim to assess how do regular fluctuations of the sex hormones during 
menstrual cycle influence hemostasis and inflammatory system. The goal was to elucidate 
fundamental mechanisms, underlying common bleeding complications in vWD-affected 
females. 
2.1 SPECIFIC AIMS  
2.1.1 Study I 
To investigate whether Swedish women diagnosed with von Willebrand disease receive 
appropriate treatment, and to assess its reliability in terms of preventing heavy 
menstrual bleeding. In addition, to evaluate the impact of excessive menstrual blood 
loss on routine activities and overall health-related quality of life. 
2.1.2 Study II 
To estimate the prevalence of postpartum hemorrhage in women with von Willebrand 
disease. In addition, we intended to find possible correlation between postpartum blood 
loss and (1) type of von Willebrand disease (2) hemostatic drug treatment (3) levels of 
coagulation factors – vWF and FVIII. 
2.1.3 Study III 
To measure thrombin generation during two phases of menstrual cycle in women with 
von Willebrand disease. To associate the results with a range of hemostatic parameters. 
To expand knowledge on mechanisms underlying heavy menstrual bleeding in women 
with vWD. 
2.1.4 Study IV 
To analyze fluctuations of the blood inflammatory and endothelial markers during a 
regular menstrual cycle and therefore to enlighten interactions between the 
inflammatory and hemostatic systems in vWD patients. 
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3 MATERIALS AND METHODS 
3.1 STUDY I 
Study participants were recruited from a register at Coagulation Unit, Karolinska University 
Hospital. This register aims to accumulate clinical data about people with bleeding disorders 
from entire Sweden. The inclusion in the register is voluntary for patients, though everyone is 
asked to participate.  
The register was filtered using the inclusion criteria: diagnosis of vWD, female gender and age 
limits 18-52 years (the latter is the average age for menopause in Sweden (210)). Invitation 
letters were sent to the eligible patients. After excluding the dropouts, 30 women were enrolled 
in the study. 
We retrieved background clinical information about each participant from the register – type 
of vWD and any pharmacological treatment. At the same time, in order to collect data related 
to menstruation and its impact we send several forms to each participant. This included 
specially designed questionnaire, pictorial blood-loss assessment chart (PBAC) and a health 
survey form (SF-36). 
3.1.1 Questionnaire 
A research team from Coagulation Unit, Karolinska University Hospital initially designed the 
questionnaire to assess impact of heavy menstrual bleeding (HMB) on everyday life activities 
(unpublished study). Originally, the questionnaire consisted of 102 questions on 11 themes, but 
in order to limit the scope of the study to relevant data only first 3 themes were included in the 
analyzed pool.  
Questions 1-12 relate to overall life conditions and are routinely used in clinical practice in 
Coagulation Unit. 
Questions 13-17, designed by the abovementioned research team, embraced menstruation 
features: duration, amount of blood loss, need for advice. 
Questions 18-29, engendered from studies by Ruta et al.(211) and Coulter et al.(212) assessed 
the impact of menstruation on everyday life activities. 
3.1.2 PBAC 
There is a well-known problem of estimating the exact volume of blood loss during 
menstruation. Being estimated by women themselves, figures may differ significantly from 
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reality. At the same time, using the preweigthened tampons and pads presents obvious practical 
inconvinience. 
Pictorial blood loss assessment chart (PBAC) is a semiobjective method, developed by Higham 
et al. (213), which makes possible to approximate accuracy in assessing volume of the 
menstrual blood loss. In this method woman quantify the number of tampons/pads used in each 
day of menstrual cycle. Depending on the degree of soaking the corresponding coefficient 
(multiplying factor) is used. At the end of menstrual cycle woman calculates the sum and if the 
latter exceeds 100 points (equals 80mL), then heavy menstrual bleeding is diagnosed (Table 
1). 
Tampons Multiplying 
factor 
Days 
1 2 3 4 5 6 7 8 
 
x1         
 
x5         
 
x10         
Pads   
 
x1         
 
x5         
 
x20         
Small blood clots x1         
Large blood clots x5         
Menstrual accidents x5         
Daily points          
Table 1. Pictorial blood loss assessment chart 
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3.1.3 SF-36 
Short Form-36 (SF-36) is a well-recognized health survey, designed to evaluate health-related 
quality of life (HRQOL) with 36 questions in 8 dimensions (Table 2). Answers to these 36 
questions were rated with accordance to SF-36 algorithms. SF-36 scale fluctuates from min=0 
to max=100 points (214). Results were compared with those obtained from Swedish general 
population (215). Reference group included 4582 Swedish women aged 15-93 years (mean 
age=42,7 years). 
Median SF-36 scores were calculated separately for each of 8 dimensions for entire study 
population and following subgroups: vWD type 1, type 2 and type 3; women with HMB, with 
normal menstrual blood loss, with no menstruation at all. 
Dimension Lowest possible score Highest possible score 
Physical functioning Very limited, including daily 
activities of personal hygiene and 
dressing 
Not limited, can perform all types 
of physical activities 
Physical health Limited performance at work or 
regular activities due to poor 
physical health 
Not limited, can perform  
Bodily pain Severe pain No pain 
General health Perceives general health status as 
poor and believes it will 
deteriorate 
Perceives general health status as 
excellent 
Vitality Feels constantly tired and worn 
out 
Feels constantly alert and 
energetic 
Social functioning Limited in social activities due to 
physical or mental health status 
Not limited, can maintain normal 
social activities 
Emotional impact Limited in work and regular 
activities due to emotional status 
Not limited, can perform work and 
regular activities 
Mental health Feels constantly depressed or 
nervous 
Feels constantly calm, in harmony 
and happy 
Table 2. Short Form-36. 8 dimensions with theirs lowest and highest scores. 
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3.2 STUDY II 
Study design was observational and retrospective.  
We analyzed data stored in the previously described register at Coagulation Unit, Karolinska 
University Hospital. Primarily, we sorted the register in consistency with inclusion criteria: 
female gender, vWD diagnosis, age 18-50 years and the history of at least one delivery. All the 
eligible women (n=47) were invited to participate with 34 of them included in the study group.  
In total, 34 women who had 59 deliveries formed the final cohort. Their age varied from 19 to 
42 years (median 32). Each delivery was supplemented with following information: hospital 
of delivery, maternal age, mode of delivery and complications, if any. Blood loss estimation 
was executed through weighing soaked materials and blood clots. Diagnosis of vWD was 
established if classical triad of bleeding episodes, family history and low vWF was fulfilled. 
Laboratory tests for vWF:Ag, ristocetin cofactor activity of von Willebrand factor (vWF:RCo) 
and their ratio helped to distinguish between subtypes of vWD. 
Finally, we also obtained characteristics of hemostatic treatment: (1) type of drug – tranexamic 
acid, desmopressin or clotting factor concentrate (2) duration of treatment (3) dose prior to 
delivery (4) total dose. 
3.2.1 Laboratory measurements 
In addition to the abovementioned data, we also collected available information regarding 
levels and activity of coagulation factors in third trimester. 
vWF was measured with either of two methods – vWF:RCo or vWF:GpIb. Methods resemble 
each other and they have similar reference ranges, which makes them comparable.  
vWF:RCo is based on the ability of antibiotic currently withdrawn from the market – ristocetin 
to increase agglutination, via enhancing vWF binding to the platelets. These aggregates drown 
to the bottom of the tube, thereby changing the optical density of the plasma. Increase of 
absorbance is then measured by photometry (216). vWF:GpIb does not need ristocetin and is 
currently used at the Karolinska University Laboratory. In this method plasma is mixed with 
reagent containing GpIb receptors (recombinant), the latter binds to vWF. Agglutination degree 
is then measured with photometry (217). 
FVIII activity (0,06 – 2,10 kIU/L) was measured using well-established method (218). This is 
an indirect enzymatic method, which is based on following process - FVIII binds to FIX and 
this complex catalyzes the activation of FX. The amount of generated FXa is proportional to 
FVIII activity. 
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3.3 STUDY III 
This was an observational study. 
The inclusion criteria were female gender, established vWD, age 18-52 and regular menstrual 
cycle (21-35 days). All the participants met conventional criteria for vWD diagnosis, though 
in some of them additional tests were previously performed, such as vWD multimer 
assessment. None of the participants were prescribed with medications that may affect 
hemostasis. This included predominantly hormonal treatment (combined oral contraceptives, 
contraceptive implants, IUDs, HRT). The exclusion criteria were irregular menstrual cycle, 
pregnancy or breastfeeding at the time of blood sampling.  
Blood samples were taken twice in each participant: first during early follicular phase (cycle 
day, cd 2-5) and second during luteal phase (cd 22-25). Blood were drawn in the morning, from 
an antecubital vein after 15 min in supine position. We used standard vacuum citrated tubes, 
that were centrifuged at 2000g for 15 min immediately after blood collection. After removal of 
the cells, plasma was centrifuged once again for another 15 min at 2000g. Platelet poor plasma 
was stored at -700C until analyzed. 
Afterwards following components were assessed: antithrombin, fibrinogen, D-dimer, 
coagulation factors II, VII, VIII, X and vWF, together with global hemostatic assay - thrombin 
generation. 
The results from the study group were then compared with those from healthy controls (n=102), 
coming from the recent study by one of the co-supervisors of the current project - Dr. Roza 
Chaireti (219). 
3.3.1 Measurement of hemostatic variables 
Thrombin generation was measured by the calibrated automated thrombogram method as 
described in the Thrombogram Guide by Thrombinoscope BV (Maastricht, the Netherlands). 
We computed following thrombin generation parameters: lag-time (time point at which 
thrombin generation starts, in minutes), time to peak (time to reach max thrombin 
concentration, in minutes), endogenous thrombin potential (ETP, total amount of generated 
thrombin, in nM*min), peak (max thrombin concentration, in nM). All samples were measured 
in triplicate. The final mixture of PPP reagent (trigger) and PPP used in the assay contained 5 
pM tissue factor (TF) and 4mN phospholipids. All reagents were obtained from 
Thrombinoscope BV, Masstricht, The Netherlands. 96-well plates used were obtained from 
Ninolab, Stockholm, Sweden. 
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Clauss method was employed to measure fibrinogen. Hemostatic variables were measured by 
means of the Sysmex CS 2000i from Siemens Healthcare Diagnostics (Stockholm, Sweden). 
Antithrombin (AT) and factor VIII (FVIII) were assessed by a chromogenic methods; factors 
II, VII and X (FII, FVII and FX) - clotting methods, von Willebrand factor (vWF:Ag) - 
immunochemical method. All reagents were produced by Siemens Healthcare Diagnostics 
(Stockholm, Sweden). D-dimer was measured by a latex-enhanced immunochemical method, 
using reagents from Medirox (Studsvik, Sweden) 
 
3.4  STUDY IV 
Study group was the same in studies III and IV and therefore inclusion criteria and 
preanalytical preparations of the blood samples were similar. 
Following inflammatory and endothelial markers were analyzed (interleukin-6 (IL-6), 
endostatin, high sensitivity C-reactive protein (hs-CRP), soluble E-selectin and P-selectin (sE-
selectin and sP-selectin), intracellular and vascular cell adhesion molecules (ICAM-1 and 
VCAM-1) and cathepsins L and S). The results were compared with corresponding date from 
the recent study by Chaireti et al. (220).  
3.4.1 Measurement of inflammatory and endothelial markers 
High sensitivity C-reactive protein was analyzed on a BS380 instrument (Mindray, 
Shenzhen, China) with CRP reagents (CRP-6K26) from Abbott Laboratories (Abbott Park, IL, 
US). The total coefficient of variation (CV) for the CRP method was 6.9% at 1.30 mg/L. 
Cathepsin L (DY952), Cathepsin S (DY1183), Endostatin (DY1098), sE-selectin (DY724), 
ICAM-1 (DY720), IL6 (DY206), sP-selectin (DY137), and VCAM-1 (DY809) were analyzed 
by the means of commercially available ELISA kit (R&D Systems, Minneapolis, MN, USA) 
according to the instructions of the manufacturer. The total CVs of the ELISAs were 
approximately 7%. 
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3.5 STATISTICAL ANALYSIS 
In all studies statistical analysis was performed using IBM SPSS statistics software for Mac 
OS version 21 (Study I and II) and 24 (Study III and IV). 
3.5.1 Study I 
The study population was arranged into subgroups according to the type of vWD and the 
amount of the menstrual bleeding. Non-parametric Kruskal-Wallis test was employed to 
compare variables, that could be ranked according to an ordinal scale.  
The median SF-36 health profiles for study participants were plotted and subsequently 
compared with those from Swedish female general population. In order to detect statistically 
significant differences between the median SF-36 values of the study population and the 
Swedish women of the general population, approximate confidence intervals with P<0.10 were 
constructed for the median values of the total study population and the subgroups with n≥15. 
The approximate confidence intervals for the median values were obtained through ranking of 
the SF-36 values in each dimension, and the results obtained were compared to corresponding 
tabulated ranks (28) for a 90% confidence interval. A 90% confidence interval was selected 
due to the size of the study population and the relatively low number of ranks obtained.  
3.5.2 Study II 
To compare the incidence of postpartum hemorrhage between the groups we used Fisher’s 
exact test, due to the small sample sizes. To compare blood loss (mL) between three types of 
vWD the Kruskal-Wallis test was used. We used Spearman’s correlation test to investigate the 
correlation blood loss during delivery and levels of coagulation factors, hemostatic drug 
treatment (dose prior to delivery). In order to compare hemostatic treatment between the groups 
with regard to its duration and total dose we used Mann-Whitney U test. 
3.5.3 Study III and IV 
Since there are no studies with a design similar to ours, i.e. measuring hemostatic (Study III) 
or inflammatory (Study IV) markers in vWD patients during the menstrual cycle, we calculated 
the required power for the cohort by using results from the studies by Chaireti et al.(219) and 
Rugeri et al. (221), where thrombin generation was measured in healthy women and patients 
with von Willebrand disease, respectively. The required cohort size in order to achieve a power 
of 0,8 with a type I-error of 5% was 12 patients. 
Due to predominant non-normal distribution and relatively small number of participants in the 
study group, non-parametric tests were chosen for calculations. We used Wilcoxon signed-rank 
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test to compare changes in variables during menstrual cycle within study group. Mann-Whitney 
U test was employed to assess differences between control and study groups. In all cases an 
exact p-value was calculated, while statistical significance was set at p < 0,05. 
3.6 ETHICAL APPROVAL 
All participants were informed about voluntary nature of the studies, as well as their 
characteristics. Written informed consent was obtained from all participants and personal data 
was made anonymous directly after collection. 
Central Ethical Review Board of Karolinska Institute, Stockholm, Sweden granted the ethical 
permission for Study I and Study II under registration №2007/1373-31/4. Studies III and IV 
were approved by Stockholm Regional Ethics Committee (№2016/503-31) and was 
subsequently supplemented with the local permission from Almazov National Medical 
Research Centre in Saint-Petersburg, Russia (№ 17/ПЦ). 
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4 RESULTS 
4.1 STUDY I 
Study cohort included 30 women with vWD aged 19-51 (mean age ± SD=35.1 ± 8.1 years). 
vWD type distribution is shown in Figure 5. Worth mentioning, that the distribution is different 
from what is observed in general population, probably due to a small sample size.  
 
Figure 5. vWD types distribution in the study cohort 
 
4.1.1 Menstruation pattern in women with vWD 
Half of study cohort reported presence of heavy menstrual bleeding, based on personal 
perceptions. However, based on clinical measurements the real incidence of HMB was shown 
to be 53.5%. The difference arises from the discrepancy between subjective and objective 
evaluations. For instance, of the 15 women who reported having HMB, only 11 (73.3%) met 
the clinical criteria for this. In contrast, 5 out of 7 women (71.4%), who reported normal 
menstrual pattern had excessive menstruations in reality. The latter illustrates the well-known 
underestimation of menstrual blood loss by women affected with bleeding disorders. This could 
happen for several reasons. Women may consider their menstruation normal just because they 
habituate themselves to this pattern. Otherwise, they may compare their bleedings with 
mother’s or sister’s, which is not a good approach, taking into account hereditary nature of 
vWD. It is worth noting, that a vice versa situation is possible (and was also present in our 
study group) with women overestimating their blood loss. All this testifies the importance of 
using more objective methods to assess menstrual bleedings. 
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Menstruation characteristics in different types of vWD are shown below (Table 3). 
Menstrual bleeding vWD type 1 
(n=15), n(%) 
vWD type 2 
(n=11), n(%) 
vWD type 3 
(n=4), n(%) 
None 3 (20.0) 3 (27.2) 2 (50.0) 
Normal 2 (13.3) 4 (36.4) 1 (25.0) 
HMB 10 (66.7) 4 (36.4) 1 (25.0) 
Table 3. Menstruation characteristics in women with different types of von Willebrand disease. vWD, von 
Willebrand disease; HMB, heavy menstrual bleeding. 
 
7 women had amenorrhea due to pregnancy or breastfeeding (2 women), combined oral 
contraceptives (COCs)(1 woman), using levonorgestrel-releasing intrauterine system (LNG-
IUS)(4 women) or previous hysterectomy (1 woman). Differences in incidence of HMB 
between different types of vWD were not statistically significant, likely due to the small size 
of the subgroups.  
4.1.2 Impact of menstruation on everyday activities 
After excluding 8 women with amenorrhea, we analyzed the impact of menstruation on overall 
life activities. It was found, that menstruations dramatically influenced women’s lives. Results 
are shown in Figure 6. 
Figure 6. Impact of menstruation on overall life activities 
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The most affected sides were mood changes (90.9%), family life (72.7%) and vacations 
(68.2%). More than half of study cohort also reported alterations in leisure activities, sex life 
and increase in anxiety (63.6% in each category). Daily activities and social relations were also 
appreciably affected (59.1% and 54.5% respectively). To a slightly less degree women reported 
negative changes in their ability to work (45.5%) or to carry out housework (36.4%). However, 
nearly one third of women was literally confined to bed during the menstrual period. 
4.1.3 Health-related quality of life  
Median SF-36 scores were compared between women with different types of vWD, patterns 
of menstruation and Swedish women in general. The results are illustrated in Figure 7. 
 
Figure 7. SF-36 profiles for different subgroups. Each point represents a median for exact dimension, while error 
bars, if present, stand for confidence intervals (p<0.10). Dotted line is for control group – Swedish women in 
general. A. The health profile for women with vWD (all types) B. The health profiles for different types of vWD 
differentially C. The health profiles of women with amenorrhea, normal menstruation pattern and HMB D. The 
health profiles of women with HMB (an excerpt from Figure 7C). vWD, von Willebrand disease; HMB, heavy 
menstrual bleeding; PF, Physical Functioning; RP, role-physical; BP, bodily pain; GH, general health; VT, vitality; 
SF, social functioning; RE, role-emotional; MH, mental health. 
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When compared median SF-36 scores of women with vWD (all types) and Swedish women in 
general, no significant differences were observed. Nevertheless, in the dimension “Vitality” 
upper limit of CI for women with vWD was equal to Swedish general population. Median 
scores for different types of vWD were also lower, though did not reach the significant 
differences (Figure 7B). It may imply the necessity to enlarge the study group in order to reach 
the level of statistical significance. Comparing different patterns of menstruation, it was 
observed that in the dimension “Bodily pain” the subgroup of women with HMB showed 
significantly lower scores (Figure 7D).  
4.1.4 Treatment for HMB 
The vast majority of women received therapy for excessive bleedings (24/30; 80%). However, 
treatment options distributed unevenly between women with different menstruation patterns 
(Figure 8).  
 
Figure 8. Pharmacological treatment in women with vWD and resulting menstrual bleeding pattern. HMB, heavy 
menstrual bleeding; LNG-IUS, levonorgestrel-releasing intrauterine system; PCP, progesterone contraceptive 
pills; DDAVP, desmopressin D-arginine vasopressin; TA, tranexamic acid; CFC, clotting factor concentrates. 
Treatment was not equally effective in all women. Based on women’s personal evaluation, 
treatment was considered to be effective in 15/24 (62.5%) of the cases, while according to the 
clinical measurements it was effective even in less number of women – 10/24 (41.7%). 
Important to notice, that 3 women with preserved menstruations received no therapy, and two 
of them met the clinical criteria for HMB. 
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4.2 STUDY II 
Study group included 34 women and 59 deliveries, occurred in 14 different obstetric clinics in 
Sweden during 1995-2012 (Table 4). 
 Type 1 Type 2 Type 3 Unknown All 
Participants 21 9 3 1 34 
Deliveries 39 14 4 2 59 
Mode of delivery 
(%) 
Vaginal 29 (74.4) 9 (64.3) 1(25) 2 (100) 41 (69.5) 
Instrumental 
vaginal 4 (10.3) 2 (14.3) 1 (25) - 7 (11.9) 
Caesarean 6 (15.4) 3 (21.4) 2 (50) - 11 (18.7) 
Induced labour (%) 7 (17.9) 5 (35.7) 1 (25) - 13 (22.0) 
Maternal age (%) 
≤23 4 (10.3) - - - 4 (6.8) 
24-30 13 (33.3) 3 (21.4) 1 (25) 1 (50) 18 (30.5) 
31-37 18 (46.2) 8 (57.1) 3 (75) 1 (50) 30 (50.8) 
≥38 4 (10.3) 3 (21.4) - - 7 (11.9) 
Parity (%) 
1 20 (51.3) 7 (50) 3 (75) 1 (50) 31 (52.5) 
2 13 (33.3) 4 (28.6) 1 (25) 1 (50) 19 (32.2) 
3 or more 6 (15.4) 3 (21.4) - - 9 (15.2) 
Birth weight (%) 
<2499 2 (5.1) 1 (7.1) - - 3 (5.1) 
2500-3999 31 (79.5) 11 (78.6) 4 (100) 2 (100) 48 (81.4) 
>4000 6 (15.4) 2 (14.3) - - 8 (13.6) 
Gestational age 
(%) 
<36 2 (5.1) - 1 (25) - 3 (5.1) 
36-41 30 (76.9) 12 (85.7) 3 (75) 2 (100) 47 (79.7) 
>41 7 (17.9) 2 (14.3) - - 9 (15.2) 
Obstetric unit in close connection with a 
coagulation unit (%) 21 (53.8) 8 (57.2) 3 (75) - 32 (54.3) 
Plasma levels checked in pregnancy (%) 26 (66.7) 13 (92.9) 4 (100) - 43 (72.9) 
Median VWF:RCo/VWF:GpIb, kIU/L 
(range) 
0.55 (0.08-
0.86) 
0.21 (0.08-
0.68) 
0.08 (0.08-
0.24) - 
0.25 (0.08-
0.86) 
Median FVIII:C, kIU/L (range) 1.07 (0.32-2.10) 
0.84 (0.63-
1.86) 
0.70 (0.06-
1.17) - 
0.94 (0.06-
2.10) 
No haemostatic treatment (%) 13 (33.3) 1 (7.1) - 2 (100) 16 (27.1) 
TA (%) 7 (17.9) 2 (14.3) - - 9 (15.3) 
TA and DDAVP (%) 11 (28.2) 1 (7.1) - - 12 (20.3) 
TA and CFC (%) 8 (20.5) 10 (71.4) 4 (100) - 22 (37.3) 
Table 4. Characteristics of the study group. vWD, von Willebrand disease. vWF:RCo, Ristocetin cofactor activity 
of Von Willebrand factor; vWF:GpIb, von Willebrand factor activity by glycoprotein Ib; FVIII:C, factor VIII 
activity; TA, tranexamic acid; DDAVP, D-amino D-arginine vasopressin; CFC, clotting factor concentrate. 
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Important to notice, that in 28 women (43 deliveries) the diagnosis of vWD was established 
prior to delivery, while in 11 women (16 deliveries) vWD was diagnosed after delivery. In the 
remaining 5 women vWD had been determined in between two pregnancies, thus they were 
included in both groups. 
4.2.1 Incidence of PPH 
The overall incidence of primary PPH was 44% (n=26), at the same time varying significantly 
between different delivery modes: postpartum blood loss exceeding 500mL occurred in 37% 
of vaginal deliveries, 57% of instrumental deliveries and 64% of caesarean sections (CS). 
Severe primary PPH (>1000mL) complicated 17% of vaginal deliveries, 43% of deliveries, in 
which forceps or vacuum were used and 18% of CS. Overall incidence of severe primary PPH 
was 20%. Secondary PPH occurred in 12% of cases. 
Vaginal hematoma developed in three patients and it was one severe bleeding complication 
from the trachea following intubation. Three patients (5%) received blood transfusions.  
4.2.2 PPH and type of vWD 
The median blood loss was higher in type 3 vWD patients compared to non-type 3, but the 
difference was not statistically significant. All types of PPH occurred more frequently in 
women with type 3 vWD (Figure 9). However, only for severe primary PPH the difference 
proved to be statistically significant (p=0.02).  
 
Figure 9. Incidence of PPH in different types of vWD. vWD, von Willebrand disease; PPH, postpartum 
hemorrhage. 
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4.2.2.1 PPH in undiagnosed vWD 
vWD was unknown at the time of 16 deliveries (11 women). Therefore, there were no 
indications for both assessment of the coagulation factors levels and prescription of the 
hemostatic drugs. The majority was subsequently diagnosed with type 1 vWD (81%), 6% - 
with type 2 and 13% - unspecified. 
The incidence of PPH was higher in women in whom diagnosis of vWD had not been 
established at the time of delivery. This was true for all types of PPH (Figure 10), though 
statistical significance was achieved only in secondary PPH (p=0.013). Blood transfusions 
were needed in three cases, where the diagnosis of vWD was unknown, compared with no 
blood transfusions in the group of known vWD (p=0.017).  
Figure 10. PPH incidence in known vs. unknown vWD at the time of delivery. vWD, von Willebrand disease; 
PPH, postpartum hemorrhage. 
4.2.3 PPH and levels of coagulation factors 
The plasma levels of FVIII and vWF were analyzed in all women, in whom diagnosis of vWD 
was established before delivery. Analyzes always took place in third trimester.  
FVIII levels were subnormal in half of pregnancies in type 3 vWD – 2/4 (50%), no pregnancies 
in type 2 vWD and in 5/26 (19.2%) of pregnancies in type 1 vWD. vWF levels were below the 
reference range in all type 3 vWD pregnancies (n=4) and almost all pregnancies in type 2 vWD 
(12/13, 92.3%). At the same time, in type 1 vWD group only 10/26 (38.5%) women had 
subnormal levels of vWF in the late pregnancy. 
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The blood loss associated with the delivery inversely correlated with levels of FVIII:C in third 
trimester (r= -0.428, p=0.01), but not with the levels of vWF (r= -0.31, p=0.6). In opposite, 
vWF levels showed moderate inverse correlation with the duration of treatment with CFC 
postpartum (r =-0.56; p=0.01), but not FVIII (r =-0.31; p=0.17) 
4.2.4 PPH and hemostatic treatment 
Exact treatment in every case was consistent with contemporary clinical recommendations 
(222, 223). 
In all women with known vWD at the time of delivery tranexamic acid (TA) was prescribed. 
TA was administered either orally or intravenously every 8 hours at the start of labor and 
continues for a median of 10 days (range 2 – 14). Desmopressin (DDAVP®, Sanofi-Aventis 
U.S. LLC)) or plasma derived factor concentrates (Haemate-P®, CSL Behring GmbH) was 
always given on top of TA. All but one woman who received desmopressin were diagnosed 
with type 1 vWD, as it considered to be more efficient in these patients. CFC was used in all 
type 3 vWD affected patients or if a trial dose of desmopressin failed to provide therapeutic 
effect. The prophylactic median dose of CFC given prior to delivery was 2000 IU (range 1000-
4000 IU). It was then prescribed as daily i/v bolus injections for a median of 9 days (range 1- 
18). The total CFC dose ranged from 2000 – 35000 IU. 
The incidence of primary PPH was higher when CFC or desmopressin was given on top of TA, 
compared with no treatment. However, in regard to severe primary PPH and secondary PPH 
the ratio turned out to be the opposite, with “No treatment” group showing the higher incidence 
of excessive blood loss. Sample size, alas, was insufficient to provide significant differences 
between different treatment subgroups (Figure 11). 
We were unable to find significant correlation between CFC given prior to and blood loss after 
delivery (r=0.03; p=0.84). There was also no association found between incidence of secondary 
PPH and duration of TA treatment (p=0.56), duration of CFC treatment (p=0.58) or total dose 
of CFC (p=0.64). 
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Figure 11. PPH incidence and mode of hemostatic treatment. 
vWD, von Willebrand disease; TA, tranexamic acid; DDAVP®, desmopressin; CFC, clotting factor concentrate; 
PPH, postpartum hemorrhage. 
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4.3 STUDY III 
12 female patients were included in the study group. Their median age was 35.0 (33.0-
41.0)(hereinafter (Median (25-75 percentiles)) and BMI=23.1 (20.2-29.4). The majority of 
patients had vWD type 1 (7 patients), type 2 was diagnosed in 3 patients (with 2 of them having 
subtype 2M), unspecified - 2 patients. 
While assessing levels of the hemostatic variables during different phases of the menstrual 
cycle in women with vWD, following differences were observed (Table 5). During follicular 
phase FVIII and FX were significantly higher, than in luteal phase (p=0.013 and p=0.033, 
respectively). Thrombin generation profiles were similar across the menstrual cycle within the 
vWD group. 
 Follicular phase (cd 2-5) Luteal phase (cd 22-25) P 
Fibrinogen, g/l 2.74 (2.37-2.92) 2.63 (2.28 - 3.02) 0.260 
D-dimer, mg/l 0.06 (0.03-0.11) 0.04 (0.02-0.08) 0.124 
Antithrombin, kIU/l 1.07 (1.02-1.12) 1.07 (1.01-1.17) 0.970 
FII, kIU/l 1.13 (1.06-1.21) 1.15 (1.12-1.20) 0.875 
FVII, kIU/l 1.11 (0.90-1.36) 1.12 (0.87-1.20) 0.240 
FVIII,kIU/l 0.87 (0.52-1.14) 0.76 (0.49-1.12) 0.013 
FX, kIU/l 1.08 (1.03-1.30) 1.04 (0.98-1.29) 0.033 
vWF, kIU/l 0.68 (0.21-1.04) 0.65 (0.20-1.02) 0.577 
Thrombin generation parameters 
Lag-time, min 3.22 (2.87-3.33) 3.00 (2.71-3.30) 0.679 
ETP, nM*min 1698.36 (1450.22 - 2021.40) 1863.57 (1417.09 - 2113.60) 0.083 
Peak, nM 215.00 (170.61 - 300.16) 242.02 (194.88 - 295.91) 0.240 
Ttpeak, min 7.33 (6.44 - 7.89) 6.95 (6.33 - 7.22) 0.520 
Table 5. Hemostatic variables during menstrual cycle in women with von Willebrand disease 
p<0,05 (statistical significance) is marked in bold 
kIU/l, kilo International Units;  
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We proceeded with comparing hemostatic variables between vWD patients and healthy 
controls, separately for the follicular and luteal phase. The ultimate results are summarized in 
Table 6.  
 Follicular phase Luteal phase 
vWD patients Healthy controls P vWD patients Healthy controls P 
Fibrinogen,g/l 2.74 (2.37-2.92) 2.58 (2.34-2.84) 0.522 2.63 (2.28-3.02) 2.67 (2.42-2.97) 0.552 
D-dimer, mg/l 0.06 (0.03-0.11) 0.06 (0.04-0.09) 0.545 0.04 (0.02-0.08) 0.06 (0.04-0.09) 0.032 
Antithrombin, kIU/l 1.07 (1.02-1.12) 0.98 (0.93-1.04) <0.0005 1.07 (1.01-1.17) 0.97 (0.93-1.03) <0.0005 
FII, kIU/l 1.13 (1.06-1.21) 0.99 (0.94-1.04) <0.0005 1.15 (1.12-1.20) 0.99 (0.94-1.04) <0.0005 
FVII, kIU/l 1.11 (0.90-1.36) 0.87 (0.76-0.99) 0.001 1.12 (0.87-1.20) 0.82 (0.73-0.93) 0.001 
FVIII, kIU/l 0.87 (0.52-1.14) 0.92 (0.78-1.09) 0.446 0.76 (0.49-1.12) 0.97 (0.83-1.08) 0.074 
FX, kIU/l 1.08 (1.03-1.30) 0.95 (0.86-1.02) <0.0005 1.04 (0.98-1.29) 0.91 (0.85-1.01) <0.0005 
vWF, kIU/l 0.68 (0.21-1.04) 0.80 (0.63-1.17) 0.059 0.65 (0.20-1.02) 0.86 (0.62-1.05) 0.044 
Table 6. Comparison of hemostatic variables during follicular (cd 2-5) and luteal (cd 22-25) phases between vWD-
affected females and healthy controls.  
p<0,05 (statistical significance) is marked in bold 
 
vWF levels were, as expected, lower in vWD group, although the p-value reached established 
level of significance only during the luteal phase (p=0.044 vs. P=0.059, during the luteal and 
follicular phase respectively). D-dimer was significantly lower also only during the luteal phase 
(p=0.032), while being similar in follicular phase. Surprisingly, AT, FII, FVII and FX were all 
significantly higher in vWD-patients, than in controls, irrespective of the phase. 
We also found significant differences in thrombin generation parameters between vWD 
patients and controls. Lag-time and time to peak were significantly prolonged in vWD patients 
compared to controls (in all cases p<0.0005), while peak thrombin concentration was decreased 
(p<0.003). In contrast, the total amount of generated thrombin, ETP, remained the same 
between the groups. The observed differences in the parameters of thrombin generation are 
graphically depicted in Figure 12. 
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Figure 12. Comparison of the thrombin generation parameters between the groups during two phases of the 
menstrual cycle.  
vWD patients are marked in plum, while healthy controls in grey. 
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4.4 STUDY IV 
The background information on the control group is similar to Study III. 
First, we compared levels of chosen variables between different phases of the menstrual cycle 
within the vWD group. The results are presented hereinafter as Median (25-75 percentiles) and 
summarized in Table 7. 
 Follicular phase (cd 2-5) Luteal phase (cd 22-25) p-value 
CATHL, pg/mL 6475.05 (3363.98 - 16656.98) 3444.47 (2091.28 - 16175.62) 0.875 
CATHS, pg/mL 4137.74 (2950.11-5524.64) 4686.90 (3743.88-6143.64) 0.239 
Endostatin, pg/mL 98066.45 (55628.48 - 132801.84) 71986.73 (52809.96 - 106878.43) 0.062 
hs-CRP, mg/L 1.34 (0.38 - 2.23) 0.47 (0.27 - 1.41) 0.155 
IL-6, pg/mL 3.99 (2.39 - 12.41) 3.64 (1.11-8.88) 0.508 
sE-selectin, pg/mL 20686.28 (16741.31 - 31344.94) 23751.68 (15575.59 - 30806.03) 0.433 
sICAM-1, pg/mL 193119.66 (177125.86 - 217278.64) 173952.76 (140408.86 - 196667.53) 0.209 
sP-selectin, pg/mL 17945.70 (12700.38 - 27885.64) 19067.49 (13170.77 - 29360.94) 0.638 
sVCAM-1, pg/mL 278598.80 (259183.24 - 328763.73) 276624.05 (248947.58 - 303147.40) 0.754 
Table 7. Inflammatory and endothelial markers during follicular and luteal phase of menstrual cycle in patients 
with vWD. 
As one may see from the above table, none of the inflammatory or endothelial parameters 
differed across the menstrual cycle, with the lowest p-value was found when comparing 
endostatin levels (although still above the established boundary, p=0.062). 
Afterwards, we compared two groups - vWD patients and healthy controls - in regard to the 
differences of the inflammatory and endothelial markers during separate phase of the menstrual 
cycle. Several parameters were found to be different. They are presented on the boxplots 
(Figure 13).  
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Figure 13. Comparison of those inflammatory and endothelial markers that differ significantly between the 
groups. vWD patients are marked in grey, while healthy controls in white. 
CATHS, cathepsin S; IL-6, interleukin 6; sICAM-1, soluble intracellular adhesion molecule 1; sVCAM-1, soluble 
vascular cell adhesion molecule 1; sP-selectin, soluble P-selectin. 
 
In all cases p-value was <0.0005, except for sVCAM-1 (Fig.13A), where it equaled 0.002 and 
0.001 during follicular and luteal phase respectively.  
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5 DISCUSSION 
5.1 STUDY I 
The first study focused on heavy menstrual bleeding and its impact on everyday life activities 
and health-related quality of life (HRQOL) in women with vWD, in Sweden. Two major 
findings were made.  
Firstly, women with vWD in their majority receive a variety of treatments aimed at reducing 
blood loss. However, despite wide treatment coverage, more than half of the women still 
experience heavy menstrual bleeding. This indicates the insufficiency of current 
pharmacological approach, as well as the demand for its optimization.  
Secondly, excessive menstrual blood loss has a substantial impact on everyday life activities in 
women with vWD, with the vast majority of them being limited in several areas. Furthermore, 
HRQOL is lower in women with vWD, compared to Swedish general population. The most 
significant difference between the groups was observed in dimension ‘bodily pain’. 
Heavy menstrual bleedings (HMB) was present in more than half of women with vWD (50.0% 
according to self-estimation and 53.3% according to objective measurements). This finding is 
consonant with the previous studies by Kirtava et al.(224), Rae et al.(225) and Byams et 
al.(226). 
The discrepancy between subjective and objective assessment of menstrual blood loss is well-
known and was present in our study. For instance, 5 women reported normal menstrual 
bleeding, albeit their PBAC score was consistent with HMB. One explanation may lie in 
hereditary nature of vWD. A woman with vWD may consider her menstrual blood flow normal 
just for the reason that it matches that of their mother or sister. Another reason might be related 
to the false subjective improvement. A woman with HMB may experience some degree of 
improvement following hemostatic treatment. However, real amount of menstrual blood loss 
sometimes remains beyond the normal values, although it somewhat decreases after the start 
of treatment. Worth noticing, that the opposite situation was also present, with 4 women 
reporting HMB, while in fact they lacked clinical criteria for HMB. 
It testifies the necessity of using validated objective or at least semi-objective bleeding scores 
in order to approximate the results to reality. In our study we used both self-reported assessment 
and pictorial blood loss assessment chart (PBAC). The accuracy of the latter was debated. 
However, the PBAC is routinely employed both in clinical practice and scientific research with 
reliable outcomes. 
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It should be mentioned, that in certain cases the size of the study group was insufficient to reach 
the chosen level of statistical significance. Nonetheless, a meticulous selection process ensured 
the reliable results, comparable with other studies. All patients were connected to hematology 
centers and had a documented diagnosis of vWD.  
Pharmacological treatment was versatile and covered the vast majority of patients (80%). 
Women who were prescribed with levonorgestrel-releasing intrauterine system (LNG-IUS) 
had normal or even no menstrual bleeding, while those receiving tranexamic acid (TA) 
continued to have HMB. This is in accordance with previous studies. Leminen et al.(227) 
reported that LNG-IUS is superior to TA in regard to reducing menstrual bleeding (83% vs. 
47%, respectively). Chi et al. (228) performed a long-term follow up study on efficacy of LNG-
IUS for the treatment of HMB in women with bleeding disorders. PBAC score was measured 
before starting the treatment and was 255 in its median (range 134–683). LNG-IUS was then 
prescribed for a median of 33 months (range 14-103) and during that period the median PBAC 
scores in women reduced to 35 (range 0–89), indicating normal menstrual bleeding. 
Furthermore, 42% of women had amenorrhea at the time of the follow-up. Authors also 
reported improvement in HRQOL and hemoglobin rise, associated with LNG-IUS use. 
In the current study, the number of vWD-affected women using LNG-IUS was low. This may 
originate from women’s reluctance towards hormonal treatment or lack of knowledge about 
LNG-IUS. Moreover, the reason for the rare use of LNG-IUS may arise from lack of medical 
counseling. 
We reported considerable limitations in everyday life activities in women with vWD, due to 
menstruation. This is consistent with recent studies (224, 225). Kirtava et al.(224) published a 
case-control study in which they had compared the impact of menstruation on overall life 
activities in women with vWD (n=62) and control group (n=70). Menstruation caused 
disturbances in life activities of 23 (32.1%) of women with vWD, compared with only 7 
(10.0%) in the control group. Rae et al.(225) examined 84 women with HMB and underlying 
inherited bleeding disorders, the majority of whom (77.5%) reported alterations in daily 
activities due to menstrual bleeding. 
The HRQOL in women with vWD appeared to be lower in comparison with general Swedish 
population. Despite the fact that statistical significance has not been achieved in every 
dimension (most likely due to small sample size), the trends are obvious and consistent with 
recent research (225, 229). In current study women with vWD had significantly lower score in 
the dimension ‘bodily pain’, compared to general population. This conforms to the study by 
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Rae et al.(225), reporting lower scores in the dimensions ‘pain’ and ‘cognition’ among women 
with bleeding disorders and HMB. Worth noticing, that according to Rae et al. women with 
vWD experienced more pain, compared with men or women with other bleeding disorders. At 
the same time, other researchers stated that dimension ‘vitality’ is negatively affected in women 
with vWD (230, 231). This should not be considered as mismatching results, but rather as a 
reflection of substantial impact of HMB on life quality. 
Summarizing the results, we reported that women with vWD in their majority receive 
pharmacological treatment for preventing bleeding episodes. However, more than half of 
women still experience HMB, which has significant negative influence on women’s everyday 
life activities and overall health-related quality of life. Therefore, the current situation reflects 
the inadequacy of current therapeutic approaches. The latter should possibly be optimized 
through intensive collaboration between gynecologists and hematologists. 
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5.2 STUDY II 
The second study aimed to evaluate the incidence of postpartum hemorrhage (PPH) in women 
with von Willebrand disease (vWD) in regard to the different types of vWD, levels of 
coagulation factors and pharmacological management. The study embraced 18 years period 
and included 14 different obstetrical units. 
The incidence of PPH was expectedly higher in women with vWD, compared with general 
population in high resource countries (232, 233). It is important to notice, that reported 
incidence of PPH varies significantly across the studies, primarily because of different study 
design. In studies, where questionnaires and self-reports were employed, the incidence of PPH 
appeared to be 31-59% (91, 158, 224, 234), while in those studies that used medical records 
and objective criteria for PPH incidence was 15-34% (235-237). This discrepancy complicates 
the comparison between studies and usually originates from differences in vWD types 
distribution within study cohort, but also unequal diagnostic approaches and management 
options. In our study group, the incidence of primary PPH was 44%, which is comparable to 
the studies where patient recall was employed, but higher than in studies with similar 
techniques of data collection. 
Median blood loss was higher in women with type 3 vWD. They also experienced PPH (of all 
kinds) more frequently than women with other types of vWD. Surprisingly, women with vWD 
type 2 were at lower risk of developing PPH than women with type 1 (p=0.02), probably due 
to overrepresentation of the latter in the group that did not receive hemostatic treatment. 
In the current study, PPH encountered frequently in all delivery modes, but especially in the 
instrumental assisted vaginal labors, where 3 out of 7 deliveries (43%) resulted in severe 
primary PPH (blood loss > 1000mL). This is substantially higher than in general population, 
where severe primary PPH occurs in 3.5% of vaginal deliveries, 8% of instrumental vaginal 
deliveries and 13% for CS (238). Our data strengthens the current recommendations to 
cautiously perform forceps/vacuum-assisted deliveries or even abstain from using these 
techniques in women with vWD in order to prevent lacerations of the maternal genital tract and 
subsequent bleeding (239). 
There are conflicting results regarding whether women with undiagnosed bleeding disorder are 
at higher risk of experiencing hemorrhages. Chee et al.(240) have analyzed data from 33 
women with vWD and concluded that the risk of PPH is higher if the diagnosis of vWD is 
established at the time of delivery. Authors have interpreted this fact as follows: women with 
apparent vWD are more likely to be diagnosed and to develop bleeding complications during 
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postpartum period. We obtained the opposite results with higher incidence of PPH in women 
with yet undiagnosed and therefore untreated vWD. The possible explanation for the 
controversy might arise from differences in prophylactic approaches. In current study all 
pregnant women with diagnosed vWD received at least antifibrinolytics before delivery, which 
is in accordance to recommendations by The Nordic Hemophilia Council (241). However, 
other routines are adapted in different countries. For instance, some authors recommend using 
TA only in case of significant decrease of vWF levels during third trimester (242, 243). 
No significant differences in PPH incidence were observed between subgroups with different 
treatment approaches: TA, TA + DDAVP®, TA + CFC. One may speculate that this is due to 
the fact that women differed in the severity of vWD, initial levels of coagulation factors, etc. 
In addition, subgroups with different treatment options were not large enough to provide 
statistically significant differences.  
There are well-recognized difficulties in estimating exact blood loss after delivery (244). 
Routines also differ distinctly between hospitals. In current study, blood loss was assessed by 
weighing the soaked materials. 
An important finding is the potential utility of FVIII level in third trimester as a predictor of 
postpartum bleeding. It has been reported that low FVIII levels may forecast surgical bleedings 
(244-246). Our results support this theory and testify similar association between obstetrical 
bleedings and low levels of FVIII (236). Important, that this remains true, even when CFC is 
prescribed preventively before labor onset, indicating the insufficiency of the therapy, at least 
in the most severe cases. The latter is further reinforced with the fact that the incidence of both 
primary and secondary PPH was higher in the study group, compared with the general 
population, even when the diagnosis of vWD was known and managed in accordance with the 
guidelines. 
Despite the fact that the obtained results require confirmation in larger cohorts, it is necessary 
to note the strengths of the current study. All patients were recruited from Coagulation Unit 
and therefore had confirmed diagnosis of vWD. Sample size of 59 deliveries is similar to 
previous reports from United States and United Kingdom (158, 236, 240). An important 
advantage of the current study is the inclusion of 11 patients with undiagnosed vWD at the time 
of the delivery. This allowed us to compare the outcomes between vWD-affected women who 
received hemostatic treatment and those who did not. 
To conclude, women with vWD in Sweden are at higher risk of developing bleeding after 
delivery. The most prominent risk factors are type 3 vWD and instrumental assisted delivery. 
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Furthermore, women with undiagnosed and thus untreated vWD have a greater risk of suffering 
from PPH. This indicates the importance of early diagnosis through rigorous assessment of 
family history with a special attention towards previous bleeding episodes. Validated bleeding 
scores, especially those that can be easily employed in antepartum clinics are also of a great 
importance. The promising significance of FVIII levels as a predictor of PPH in women with 
vWD should be further assessed in the larger studies. 
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5.3 STUDY III 
To the best of our knowledge changes in hemostatic variables during regular menstrual cycle 
has never been assessed previously in women with vWD. We observed lower levels of FVIII 
and FX during the luteal phase, compared to the follicular phase in vWD affected females. 
When comparing vWD group and controls, we found higher levels of several coagulation 
factors in the study group - FII, FVII and FX. Thrombin generation profiles were also different 
and characterized by prolonged lag-time, time to peak and reduced peak thrombin 
concentration. At the same time, total amount of generated thrombin was similar between the 
groups. 
Coagulation system is known to respond sensitively to the changes both in external and internal 
environment. In women, cyclic changes of sex steroids during the menstrual cycle also 
modulate functioning of hemostasis, although ultimate effect is still yet to be clarified, despite 
intensive research within the field (247-251). At the same time, understanding of how does 
exactly menstrual cycle affect coagulation is extremely important both for fundamental science 
and clinical routine. It may potentially help to enlighten basic mechanisms of coagulation and 
to choose a proper timing for coagulation analyses during the menstrual cycle.  
We found lower levels of FVIII and FX during the luteal phase, compared to the follicular 
phase in women with vWD. The latter was also demonstrated in the recent study on healthy 
volunteers by Chaireti et al. (219). FVIII was a subject to a number of researches, with the 
majority of them reported no cyclic variation in its levels (252-258), while others found its 
lowest levels during menstruation or early follicular phase (259, 260). The decrease in FVIII 
and FX, active procoagulant factors, during the luteal phase may predispose women to 
excessive bleeding during menstruation - the common complication of vWD (261). 
Thrombin generation profiles did not differ across the menstrual cycle in women with vWD, 
which is in contrast to the control group, where ETP increased during the luteal phase. 
However, it is difficult to establish whether there is actually no difference or the sample size is 
not large enough to provide reliable results. 
When comparing vWD patients and healthy controls, more pronounced differences were 
found.  
Thrombin generation profiles were significantly different between the groups, irrespective of 
the phase. Lag-time and time to reach peak thrombin concentration were prolonged in women 
with vWD compared to controls (p<0.0005 for all cases), while maximum thrombin 
concentration was lower (p=0.003 and p=0.002 during follicular and luteal phase respectively). 
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The total amount of the generated thrombin was similar between the groups in either phase. 
Therefore, the thrombin generation curve became flattened, with a gentle rise and decreased 
peak. This observation is consistent with previous studies (221). Based on that, one may 
speculate that in order to achieve effective hemostasis it is more important to reach peak 
thrombin concentration faster, than to generate somewhat total thrombin amount over a longer 
period. Obviously, this idea should be corroborated by exact clinical data. Summarizing, 
thrombin generation assay, which is often used today to evaluate hemostasis, has confirmed its 
usefulness in differentiating patients with the vWD and healthy controls. 
We also observed higher levels of FII, FVII and FX in vWD group, compared to controls 
(p<0.0005; p=0.01; p<0.0005 respectively). It could be hard to draw robust conclusion from 
this observation. Probably, some uncontrolled confounders might be involved. This may 
include but not be limited to the blood group, smoking status or chronic inflammation. 
Important to mention, that increase in procoagulant markers might reflect the activation of 
hemostasis in order to compensate for the bleeding. 
During luteal phase, D-dimer was lower in vWD group, compared to controls (p=0.032). The 
previous studies on D-dimer levels during menstrual cycle reported conflicting results (255, 
262). It is possible, that relatively higher levels of D-dimer during early follicular phase (which 
corresponds to the menstrual phase of the uterine cycle) may reflect activation of fibrinolysis 
within the uterine cavity. 
Another interesting finding was higher AT levels in women with vWD, compared to controls, 
both during follicular and luteal phase (p<0.0005). AT expresses its anticoagulant properties 
through inhibiting serine proteases (i.a. thrombin). Therefore, we speculate that increase in AT 
among women with vWD might contribute to diminished thrombin generation and 
subsequently development of bleeding complications. 
The current study has several limitations. We performed blood tests twice during the menstrual 
cycle, which might be considered insufficient, although remains comparable to previous 
studies. Recent systematic review by Knol et al. (251) reported that studies differ significantly 
in regard to number of sampling and exact day within the menstrual cycle. At the same time, it 
is important to balance the scope of the study with the patients’ risks due to relative 
invasiveness of the procedure. In the current study we have not controlled the participants for 
the blood groups. It has been previously shown, that blood group may affect the blood levels 
of FVIII and vWF. ABO glycoproteins are intimately intertwined with vWF, which leads to 
the fact, that people with 0 blood group have lower levels of vWF than those from non-0 group. 
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At the same time, belonging to a particular blood group can hardly explain all observed 
differences in other hemostatic variables. Lack of patients with type 3 vWD might be 
considered as a drawback. This is due to relative rarity of the patients and, as a results, 
difficulties in recruiting them. However, the majority of vWD patients have type 1, which 
makes the results of the current study applicable to the real situation. 
The main strength of the current study is stringent inclusion criteria. Normally, women with 
vWD are often prescribed with hormonal treatment in order to control bleeding episodes during 
menstruation. In our study, none of the participants received hormones in any form. This was 
done in order to avoid bias, resulting from the influence of hormones on hemostasis.  
To conclude, women with vWD are different from healthy controls with regard to the levels of 
hemostatic parameters. Interestingly, these differences were largely constant across the 
menstrual cycle. Based on that, it sounds reasonable to speculate that coagulation tests and 
especially global hemostatic assays, such as thrombin generation, regardless of the timepoint 
may still provide valuable information. 
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5.4 STUDY IV 
In women, periodic fluctuations of the sex steroids during the menstrual cycle influence many 
body functions, including immune system. Summarizing the previous findings one can deduce 
the following pattern. Immune system is more active during the follicular phase, reflecting the 
rise in estrogen, followed by decrement during the luteal phase, which is at least partly 
dependent on the rise of the anti-inflammatory progesterone (263-265). Activity of the immune 
system peaks at the time of menstruation, the latter is considered to be an acute inflammatory 
event (266, 267). At the same time, inflammatory system and coagulation intertwine intimately, 
sharing the common pathways and influencing each other (268, 269). Therefore, the available 
data indicates the existence of a flexible cooperation between female reproductive system, 
inflammatory system and coagulation. In the current study we analyzed changes in the blood 
levels of the inflammatory and endothelial markers during a regular menstrual cycle in women 
with vWD. 
Endostatin levels were higher during the follicular phase, although the difference was not 
significant (p=0.062). Endostatin expresses anti-angiogenic properties, but also modulates 
coagulation cascade, through upregulating plasmin production and downregulating FVII, FX, 
FXI, FXII, tissue factor and, interestingly, vWF (270, 271). Early follicular phase (cd 2-5) 
corresponds to the menstrual phase of the uterine cycle. During this period active angiogenesis 
occurs within the basal layer of the endometrium. It seems possible to hypothesize, that through 
synergism of the anti-angiogenic and anti-coagulant properties, endostatin contributes to the 
development of heavy menstrual bleeding - the common complication in vWD affected 
females.  
Other variables did not differ between the phases, which may be due to a small number of 
participants in the study group.  
When comparing vWD females and healthy controls, we found lower sP-selectin levels in the 
former group. P-selectin shares the storage site with vWF, i.e.Weibel-Palade bodies in 
endothelial cells and ⍺-granules in platelets. One may speculate, that decrease in p-selectin 
levels among patients with vWD might reflect the alterations in the transportation or storage 
routes, common for vWF and p-selectin. Furthermore, upon stimulation with triggers, e.g. 
thrombin, P-selectin becomes externalized on the cell surface, facilitating platelet adhesion to 
endothelium. Therefore, lower p-selectin levels may potentially contribute to increased 
bleeding tendency in women with vWD. 
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We also observed differences in several markers, that influence angiogenesis. sVCAM-1 was 
lower in women with vWD, compared to controls during both phases of the menstrual cycle. 
VCAM-1 was previously reported to take part in de novo vessel formation, including 
cytokines-induced neoangiogenesis (272, 273). In contrast, sICAM-1 levels were higher in 
women with vWD, than in control group. Among other functions, sICAM-1 facilitates 
transendothelial migration of leukocytes, which antecedes neoangiogenesis with the 
inflammatory loci (274). sICAM-1 is triggered with a variety of stimuli, i.a. IL-6, the latter was 
also higher in vWD group. IL-6 has myriad of functions, both pro- and anti-inflammatory, 
including its influence on angiogenesis. Gopinathan et al. demonstrated that IL-6 promotes 
formation of defective vessels (275). 
In addition, cathepsin S was lower in vWF group, than in healthy controls. This protease 
participates in extracellular matrix degradation, which is crucial for neoangiogenesis. 
Deficiency in cathepsin S was demonstrated to cause suppression of angiogenesis.  
To summarize, we found that women with vWD differ from healthy controls with the levels of 
mediators, that play role in angiogenesis. Such dysregulation of pro- and anti-angiogenic 
substances may potentially contribute to the development of the specific complication of vWD 
- angiodysplasia. As it was written before, this term means the formation of the ectatic vessels 
with abnormal structure in different body regions, predominantly gastrointestinal tract (200, 
276). It is assumed that the formation of angiodysplasia is directly related to the lack of vWF, 
which negatively modulates angiogenesis. Our results suggest, that other potent markers may 
also play role. It is important to note, that our study was not initially designed to study 
angiodysplasia. Therefore, the findings require further verification. Decreased levels of 
cathepsin S and p-selectin among patients with vWD, compared to controls, might contribute 
to the development of the bleeding complications, i.a. heavy menstrual bleeding. 
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6 GENERAL CONCLUSIONS 
• The majority of women with von Willebrand disease receive versatile pharmacological 
treatment as a prophylaxy of the bleeding episodes. However, current therapeutic 
approaches are insufficient to prevent excessive blood loss during menstruation, since 
more than half of the women meet the clinical criteria for HMB.  
• Excessive menstrual blood loss significantly influences women’s lives, causing 
alterations in everyday life activities and diminishing the overall health-related quality 
of life. 
• Despite the reported efficacy of hormone-releasing intrauterine devices in preventing 
heavy menstrual bleedings, their use among women with vWD remains low. An 
appropriate counseling on the advantages and actual side effects of the intrauterine 
devices could potentially encourage women to opt for LNG-IUS. 
• Current clinical management of vWD-affected women should be optimized in order to 
reduce frequency of the HMB episodes and their impact on overall life activities. This 
could potentially be done through intensive collaboration between hematologists and 
gynecologists.  
• Despite wide treatment coverage, women with vWD are still at higher risk of PPH, with 
certain subgroups being at even greater risk of experiencing major bleeding after 
delivery. Among different types of vWD, women with type 3 are more likely to suffer 
from bleeding complications following delivery. 
• Instrumental assisted delivery represents an independent bleeding risk factor with 
almost half of vWD-affected women experiencing blood loss more than 1000mL. This 
reinforces the recommendations to avoid using forceps and/or vacuum in this cohort. 
• Women with vWD undiagnosed at the time of the delivery have a higher risk of 
developing PPH. In order to overcome this challenge, a thorough identification of vWD 
patients is required. Validated blood scores provided in the antenatal settings are 
potentially beneficial. 
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•  Levels of FVIII measured in the late-pregnancy could serve as the predictor of PPH in 
women with vWD.  
• In women with vWD, procoagulant factors FVIII and FX are lower during the luteal 
phase, which may predispose them to bleed excessively during menstruation. 
Furthermore, higher antithrombin levels in vWD-affected females compared to healthy 
controls, may also contribute to the development of the bleeding complications. 
• vWD-affected females require longer time to reach peak thrombin concentration, with 
the latter still being lower, than in healthy women. This implies, that dynamics of 
thrombin generation, i.e. rapid reaching the maximum thrombin concentration is 
essential to ensure effective hemostasis. 
• Endostatin, which exhibits antiangiogenic and anticoagulant properties, is higher 
during early follicular phase , than in luteal phase in women with vWD. This may 
potentially contribute to the development of heavy menstrual bleeding, since reliable 
hemostasis and the formation of new vessels within the endometrium are both essential 
for the menstrual bleeding cessation.  
• P-selectin levels are lower in women with vWD, compared to healthy controls, which 
may increase the bleeding tendency, since p-selectin promotes platelet aggregation.  
• Levels of several proteins, regulating angiogenesis (sICAM-1, sVCAM-1, cathepsin S 
and IL-6) differ in patients with vWD, compared to healthy controls. This 
hypothetically contributes to the formation of angiodysplasia - common complication 
of vWD. 
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7 FUTURE PERSPECTIVES 
 
While working on our project, as well as studying the results of other researchers, I realized 
that currently there are a lot of yet unresolved and controversial issues related to vWD, both in 
fundamental science and routine clinical practice. In part, this situation is due to the fact that 
vWF is a multifunctional agent that takes part in the development of many diseases.  
In our project, participants were included in the study group based on stringent inclusion 
criteria. Therefore, they represent a valuable cohort, eligible to participate in the further studies 
on vWD. Following are some reflections on vWD, that, in my opinion, are of a notable interest 
for future researches. 
Growing evidence suggests vWF role in the progression of cardiovascular diseases. Higher 
vWF levels in patients with atrial fibrillation present an independent risk-factor with major 
adverse events and all-cause mortality (277). In accordance with recent population-based study, 
rise in vWF and decrease in ADAMTS13 activity are associated with dementia (278). 
Therefore, it may be fruitful to collaborate with cardiologists on assessing the prevalence of 
cardiovascular diseases in our vWD group. 
vWF is now also considered to play a substantial role in oncogenesis. Although this role is yet 
to be scrutinized, the most recent studies suggest the bidirectional effect, both in tumor 
progression and cancer cells apoptosis (279). Furthermore, elevated levels of vWF were 
reported for many malignant diseases and at least for some of them, vWF levels correlate with 
disease progression (280-283). The exact causality still remains to be described. A possible aim 
for a future research may be to study our vWD cohort in regard to the development of the 
malignancies among them. Due to the relative young age of participants and in order to enrich 
the study group, it may be reasonable to retrieve medical information on their relatives. 
Emerging role of vWF in angiogenesis is another exciting field with many unsolved issues 
(136). In our study #4 we have also demonstrated the altered balance of pro- and anti- 
angiogenic mediators in patients with vWD, compared to controls. Since the abovementioned 
study was not initially designed to study angiodysplasia, it would be of a great interest to design 
such study. This could potentially bring new insights on common vWD complication - 
formation of angiodysplastic lesions. Furthermore, this may also provide a valuable 
information on other disorders, related to mesenchymal dysplasia - Ehlers-Danlos syndrome, 
Dieulafoy’s vessels, multiple skeletal abnormalities, etc., since vWD often co-occurs with 
them. 
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The angiogenic properties of vWF present a great clinical importance, as angiogenesis is 
currently considered to play substantial role in the progression of the various diseases, 
including malignancies. Studying vWF-angiogenesis relations may potentially pave the road 
to the new therapeutic options for cancer patients.  
Undoubtedly, the development of the new scientific technologies will bring new insights and 
provide valuable information on vWD. To name few, using blood outgrowth endothelial cells 
(BOECs) to study basic mechanisms of vWD development or employing untargeted approach 
(omic-technologies) (284). 
The development of the new drugs for vWD treatment is crucial for improving quality of life. 
A candidate option is interleukin-11, which was shown to increase plasma vWF and reduce 
bleeding symptoms, i.a. among patients refractory to DDAVP (285, 286). Another promising 
agents are aptamers - the new set of drugs, oligonucleotides, that may specifically block various 
proteins. For instance, an aptamer ARC1779 connects to the A1 domain of vWF, blocking its 
capacity to bind platelets. This may potentially be used in treating 2B vWD patients (287, 288). 
Simultaneously, our project has demonstrated that the most effective current treatment option 
for excessive menstrual bleeding - LNG-IUS, is not widely used among patients with vWD, 
probably due to the prejudices towards hormonal treatment. It is of a great clinical importance 
to provide a reliable and most up-to-date information on the current treatment options of vWD-
related gynecological complications. This might be done through designing popular science 
articles or a brochure to be distributed in the respective groups. 
vWF has many functions, that extend far beyond the hemostasis itself. Therefore, careful study 
of the basic mechanisms of vWF functioning will help not only patients with vWD, but 
hopefully also those who suffer from a number of other diseases, in which vWF also plays role 
- autoimmune diseases, malignancies and atherosclerosis, etc. Furthermore, this will help us to 
better understand the mechanisms of inflammation and angiogenesis. 
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